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“…I feel absolutely clean inside, and there is nothing but pure euphoria. I have never felt 
so great, or believed this to be possible. The cleanliness, clarity, and marvelous feeling of 
solid inner strength continued throughout the rest of the day, and evening, and through 
the next day. I am overcome by the profundity of the experience…” 
 
- Alexander Shulgin, commenting on the subjective effects of 120 mg MDMA 
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Abstract 
 
INTRODUCTION 
In recent years there has been a large increase in the use of a new kind of amphetamine-
type stimulants known as substituted cathinones. These compounds have a short history 
of human use, and little is known about their potential neurotoxicity. Two of the most 
popular substituted cathinones, 4-methylmethcathinone (4-MMC, mephedrone) and 3,4-
methylenedioxymethcathinone (MDMC, methylone) are, aside from their β-ketone 
group, close structural analogues of potentially neurotoxic amphetamines such as 
methamphetamine (METH) and 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). 
This has led to concern about the potential neurotoxicity of these novel compounds, and 
warrants a closer investigation into their possible long-term neurotoxic effects. 
 
METHODS 
The long-term effects of METH and MDMA as well as 4-MMC and MDMC were assessed 
using a range of biochemical assays, including assessment of monoamine levels and their 
transporters. The effects on brain activity were investigated using manganese-enhanced 
magnetic resonance imaging. Furthermore, behavioral experiments assessing cognition 
and neuropsychiatric function were performed. Finally, in vitro experiments in a 
neuroblastoma cell line were performed to identify mechanisms responsible for the 
observed differences in toxicity between the amphetamines and cathinones. 
 
RESULTS 
Unlike METH and MDMA, which produced strong reductions in dopamine and serotonin 
levels or brain activation, 4-MMC produced few notable effects on monoamine levels and 
had only minor effects on brain activation, although MDMC produced a reduction in 5-HT 
levels similar to MDMA.  No clear effects on behavioral tests of memory function were 
observed as both increases and decreases in test performance were seen following 4-
MMC and MDMC. In vitro experiments revealed that cathinones differ from 
amphetamines in their redox properties, and 4-MMC produced different effects than 
METH on the mitochondrial electron transport chain. 
 
CONCLUSIONS 
The substituted cathinones 4-MMC and MDMC do not appear to be more neurotoxic than 
METH and MDMA. If anything, they show a more favorable safety profile.  Therefore, 
these substances do not appear to present an imminent and severe threat to public 
health. From a harm reduction perspective, these compounds may be good alternatives 
to METH and MDMA. However, future work is needed to assess with certainty the long-
term effects of amphetamine-type stimulants in humans. 
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1. Introduction 
 
Amphetamine-type stimulants comprise a wide range of substances including 
amphetamine, methamphetamine and ecstasy which have been used medically and 
recreationally for decades. They belong to a class of drugs known as psychostimulants 
that, when consumed, produce sensations of euphoria, decreased need for sleep, and 
increased levels of energy and mental alertness. The fact that these drugs exert such a 
powerful stimulatory effect on the brain has led to questions and concern about their 
potential neurotoxicity. Just as researchers were attempting to answer these questions, a 
game-changing development occurred on the worldwide illicit drug market. 
 
Between 2000 and 2010 the use of Internet increased rapidly, becoming an integral part 
of everyday life and the preferred method of communication in many parts of the world. 
A revolution in commerce ensued, and companies such as Amazon introduced the world 
to the concept of e-commerce: the possibility of buying goods on the Internet with the 
click of a button. It was around this time that some Internet vendors began selling a wide 
range of novel psychoactive substances for recreational use that had little or no history of 
human consumption. Amongst the most popular new drugs were the ones that belong to 
a particular kind of amphetamine-type stimulants known as cathinones. 
 
Cathinones are very, but not entirely, similar to normal amphetamines: although they 
produce almost identical euphoric and wakefulness-promoting effects, the slight changes 
in their molecular structure meant they were not covered by existing drug laws, and could 
therefore legally be distributed and sold. The term “designer drug” which is often used 
for these drugs, actually refers to the notion that the molecules are specifically designed 
to circumvent drug laws. More recently, they have also been known as “bath salts” or 
“plant food”, labels initially applied to these substances by Internet vendors in order to 
circumvent laws banning their sale for human consumption.  
 
The explosive increase in popularity of these new, legal and widely available drugs 
sparked a panic in media and politics about the possible dangers of these novel 
compounds. Sensationalized tabloid reports of violence, self-mutilation and even 
cannibalism occurred frequently. Although these reports were mostly false or 
exaggerated, they did point out some important questions. What risks are people taking 
by consuming these new substances? Are they neurotoxic, or do they produce any 
serious long-term effects on the brain? If so, are these cathinones more or less harmful 
than the well-known, normal amphetamines? 
 
It is the goal of this thesis to provide answers to some of these questions, as they will 
provide urgently needed information that is important for the development of an 
effective and evidence-based public health policy and harm reduction approach with 
regards to these new substances. 
  
10 
 
2. Literature review 
 
2.1 Overview 
 
The literature review is organized as follows. First, a brief description of a number of 
important terms, such as amphetamines, cathinones, and the differences between them 
will be explained.  After this, a section is devoted to the history of amphetamines and 
their impact on society. Subsequently, a short review of the 5-HT, DA and NE 
neurotransmitter systems will be given, as these systems are the primary targets of 
amphetamines. The next section extends on this, and discusses in more detail the 
pharmacology and mechanisms of action of amphetamines in the nervous system.  
 
After this general overview, the focus will shift towards the primary topic of this thesis, 
namely the alleged long-term neurotoxic effects of amphetamine-type stimulants. The 
existing evidence of neurotoxicity in both humans and animal models will be reviewed 
broadly, and include a discussion of studies ranging from neuroimaging and 
neurocognitive studies in humans to preclinical studies employing biochemical as well as 
behavioral methods. Finally, the last section of the review deals with the proposed 
mechanisms underlying the development of amphetamine neurotoxicity, and focuses 
primarily on preclinical and in vitro mechanistic studies that provide clues about the 
mechanisms involved in producing amphetamine neurotoxicity. 
 
2.2 Defining amphetamine-type stimulants  
 
The pharmacology and toxicology of amphetamine-type stimulants is the primary topic of 
this thesis. Understanding the terms used to refer to amphetamine-type stimulants can 
be can be somewhat complicated, particularly in the case of this thesis, which deals with 
two different kinds of amphetamine-type stimulants, namely amphetamines and 
cathinones: two closely related, but not entirely similar substances. For clarity, a brief 
description of these terms is provided here. 
 
Amphetamine-type stimulants – amphetamine-type stimulants is a catch-all phrase for all 
amphetamines, cathinones as well as other drugs that resemble amphetamines in their 
structure or pharmacological action, such as methylphenidate. 
 
Amphetamine and amphetamines – the word amphetamine is a contraction of α-methyl-
phenethylamine. In the strictest sense of the word, amphetamine refers to the 
corresponding molecule shown in Fig 2.1. The phenethylamine part of the word refers to 
the most basic “backbone” of the molecule consisting of a 6-carbon phenyl ring 
connected to an amino (NH2) group by a two-carbon side chain. The carbons in the side 
chain are referred to as α and β carbons. The α-carbon, located closest to the amino 
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group, has a methyl (-CH3) group attached to it, hence the α-methyl part of the name. 
When referring specifically to this molecule, the abbreviation AMPH will be used in this 
thesis. As Fig. 2.1 shows, the basic amphetamine structure is not unique to AMPH. The 
amino group can be methylated and functional groups can be added to numerous 
locations on the ring and side chain of the amphetamine molecule, producing a vast 
number of different substances, for instance METH and MDMA. This entire group of 
compounds is known as substituted amphetamines or just amphetamines for short. In 
this thesis, the terms amphetamine and amphetamines refer to any specific 
amphetamine or to the entire group of amphetamines, rather than AMPH specifically. 
 
Cathinone and cathinones – In the strictest form, cathinone is an AMPH molecule with a 
specific substitution: namely a ketone group on the side chain β carbon (Fig. 2.1). It 
derives its name from the fact that it is the primary psychoactive compound of the Catha 
edulis plant. Similar to AMPH, cathinone can also have functional groups added to it, 
producing a large possible variety of so-called substituted cathinones, or cathinones for 
short. In this thesis, the term cathinone or cathinones will refer to any specific cathinone 
or to the entire group of cathinones. The substances 4-MMC and MDMC, also known as 
mephedrone and methylone (Fig. 2.1) are examples of such cathinones, and will play a 
key role in this thesis.  
 
Β-keto amphetamines and non-keto amphetamines - due to the ketone group on the β 
carbon, cathinones are sometimes also referred to as β-keto amphetamines or simply 
keto amphetamines. In contrast, normal amphetamines can be referred to as non-keto 
amphetamines. Cathinones can best be viewed as a subtype of amphetamines. 
Importantly, this implies that all cathinones, by definition, are amphetamines, but only 
amphetamines with the β-ketone group are cathinones. For this reason, the terms β-keto 
amphetamine, keto amphetamine and non-keto amphetamine will also be used in this 
thesis when appropriate to avoid any ambiguity. 
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Figure 2.1 Molecular structures of amphetamine-type stimulants mentioned in this thesis. 
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2.3 History of amphetamines 
2.3.1 Amphetamines in pre-industrial societies 
 
There is evidence that the psychoactive and stimulating effects of amphetamines have 
been known to humans for millennia. The Ephedra sinica plant, which contains ephedrine 
(Fig. 2.1), a stimulant closely related to AMPH, has been found in Neolithic archeological 
sites in the Middle East and India. It has been suggested that Soma, the Vedic ritual drink 
mentioned in the Rigveda, may have been an Ephedra-containing concoction, although 
other psychoactive constituents, such as Amanita muscaria, have also been mentioned as 
possible candidates (Furst, 1976; Mahdihassan and Mehdi, 1989). Clearer evidence of its 
use comes somewhat later, from a first century AD Chinese text that details the use of 
ephedra for treating asthma and upper respiratory infections, suggesting that also its 
medical applications have also been known for a long time (Sulzer et al., 2005). 
 
A second example of the lengthy history of human amphetamine use is the consumption 
of the Catha edulis plant, which is commonly consumed by chewing fresh leaves of the 
plant for an extended period. The compound responsible for the psychoactive effect of 
the khat plant is cathinone. Khat is frequently used in the Arabian Peninsula and parts of 
Africa. Exactly when the chewing of khat was introduced in these societies is not known, 
with estimates ranging between 525 AD and the 13th century. However, it is clear that 
since the 13th century, khat has been widely enjoyed for its psychoactive and stimulating 
effects and as a social ritual. At present, it is estimated that between 80-90% of adult 
males and 10-60% of adult females in these regions consume khat on a daily basis  
(Elmi, 1983; Pantelis et al., 1989; Al-Motarreb et al., 2002; Warfa et al., 2007) 
 
2.3.2 Synthetic amphetamine and methamphetamine 
 
Although amphetamines have been used for thousands of years, the chemical synthesis 
of AMPH is a more recent event that was first described by Rumanian chemist Lazar 
Edeleanu (Edeleano, 1887). However, the drug received relatively little attention until its 
psychostimulant properties were discovered several decades later (Alles, 1933). It was 
first introduced commercially in 1932 by Smith Kline and French, under the trade name 
Benzedrine, as an inhaler for treating asthma and allergies, as it effectively enlarged nasal 
and bronchial passages. After its introduction in tablet form in 1936 it quickly became one 
of the most popular and well-known drugs of all times. Its effects were welcomed by 
people across different social strata and professional groups, ranging from stay-at-home 
moms and truck drivers to artists, musicians and scientists. The surge in popularity led to 
AMPH being scheduled as a prescription-only medicine in 1939, in an attempt to decrease 
its use. However, due to aggressive marketing by the pharmaceutical industry – AMPH 
was marketed for treating anything from hay fever, fatigue and obesity to depression,  
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schizophrenia and even opiate addiction - and high demand for the drug, its use only 
increased. By 1970 the pharmaceutical industry produced 10 billion tablets and it is 
estimated that 50-90% of this amount was re-sold or otherwise diverted to the black 
market (Sulzer et al., 2005; Rasmussen, 2008b). 
 
Shortly after AMPH, the synthesis of METH was first described in 1893 by Japanese 
chemist Nagai Nagayoshi (Grobler et al., 2011). Just like AMPH, METH was embraced by 
pharmaceutical companies for similar indications. For instance Obetrol, a mixture of 
AMPH and METH, became a highly popular weight loss drug in the 50’s and 60’s 
(Rasmussen, 2008a). The use of METH by the German armed forces during World War II 
has been well-documented. Although Nazi officials formally discouraged the use of METH, 
it is clear that some commanding officers would give the drug to their soldiers to combat 
fatigue during long missions. The METH, which was sold in Germany under the trade 
name Pervitin was referred to by the soldiers as tank chocolates (“Panzerschokolade”) 
(Hurst, 2013). Notably, amphetamines are currently still in use by armed forces up until 
this day (Estrada et al., 2012). 
 
Today, AMPH remains a widely used drug. Although the number of indications for which 
AMPH is commonly prescribed has decreased significantly, it still remains one of the 
primary treatments for ADHD, a disease affecting up to 5% of the adult population, with 
an even higher prevalence in children (Wigal, 2009; Willcutt, 2012). Furthermore, AMPH 
is commonly prescribed off-label for a number of other disorders (Bazzano et al., 2009). 
Importantly, aside from its medical uses, amphetamines are also widely used 
recreationally. According to the United Nations Office on Drugs and Crime, 
amphetamines are the second most widely used illicit drug in the world, after cannabis 
(UNODC, 2011). Therapeutic doses of AMPH and METH are in the range of 10-60 mg/day, 
corresponding to approximately 0.1 – 0.8 mg/kg/day for an 80 kg individual, while 
recreational doses are commonly north of this number.   
 
2.3.3 Rise of MDMA  
 
Aside from AMPH and METH, another drug known as MDMA or ecstasy, has also had a 
significant influence on society, albeit primarily as an illegal drug. MDMA was originally 
developed by Merck in 1912, but did not become widely known until after it was first 
resynthesized by American medicinal chemist Alexander Shulgin in 1965. In an effort to 
determine the psychoactive properties of the drug, Shulgin (1995) tested it on himself 
and discovered that MDMA, in addition to possessing the known wakefulness promoting 
effect of amphetamines, also produced a number of very different effects, such as an 
increased willingness to communicate and feelings of love, empathy and closeness to 
others. Later the term empathogen or entactogen was coined to refer to substances 
producing these types of effects. Shulgin realized that these effects might make the drug 
an effective tool in aiding psychotherapy sessions by improving communication between 
15 
 
patient and therapist. He introduced the drug to psychotherapists, and the drug was used 
fora period of time for this purpose. However, as more people became familiar with its 
effects, its recreational use increased rapidly, and in 1985 the US Drug Enforcement 
Agency scheduled MDMA as a controlled substance (Benzenhofer and Passie, 2010). 
Despite its legal status, the drug is still one of the most widely used drugs in the world 
and has exerted tremendous influence on music, nightlife and festival culture (Reynolds, 
2013). Interestingly, there has recently been renewed interest in the possible clinical 
applications of MDMA as initially envisioned by Shulgin (Mithoefer et al., 2011; Oehen et 
al., 2013). A common dose of MDMA is around 100 mg, which corresponds to 1.3 mg/kg 
for an 80 kg person, and in the abovementioned clinical study the initial dose was 125 mg. 
However, in recreational settings, MDMA is commonly (but not always) consumed in the 
form of ecstasy pills containing variable amounts of MDMA, making it difficult for users to 
accurately dose the drug (Morefield et al., 2011). 
 
2.3.4 Substituted cathinones and the new drug market 
 
Prior to the turn of the century, the amphetamines in widespread recreational use were 
limited to AMPH, METH and MDMA. All three of these substances are subject to tight 
legal control measures. Sale and possession of these substances is illegal and they are 
covertly distributed to users via the black market. However, this was all about to change. 
Between 2000 and 2010, advances in information technology and infrastructure 
drastically increased the percentage of households with an Internet connection. This 
caused revolutionary changes in communication patterns and increased the ability of 
people all over the globe to exchange information with each other. These developments 
eventually led to a second revolution, namely in commerce, as companies such as 
Amazon introduced the world to the concept of electronic commerce – the possibility of 
buying goods at the click of a button without having to leave your house. 
 
The Internet revolution did not go unnoticed to the drug market either. Towards the end 
of the first decade of this century, the number of Internet vendors selling a variety of 
novel, hitherto practically unknown, psychoactive substances increased exponentially. 
Figure 2.2 shows the number of novel psychoactive substances reported through the 
EMCDDA early warning system from 2005 – 2013, and shows the large increase of novel 
psychoactive sbustances starting around 2009. 
 
Amongst the most popular substances are the substituted cathinones. As described 
previously (see Fig. 2.1), the chemical structure of cathinones is very similar to that of 
amphetamines. It is therefore not entirely surprising that they also produce almost 
identical euphoric and wakefulness-promoting effects. In fact, the primary reason that 
these cathinones quickly became so popular was because they caused similar pleasant 
subjective effects as amphetamines, but due to the ketone group on the β carbon, were 
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not covered by existing drug laws. They could therefore be legally distributed and sold in 
this vast, newly developed, online e-commerce-based grey market (Power, 2013). 
 
The term “designer drug” which is often applied to these types of drugs, actually refers to 
the idea that the molecules are specifically designed to circumvent drug laws. More 
recently, however, the cathinones have also been known as “research chemicals”, “bath 
salts” or “plant food”, referring to labels that vendors would place on the products in 
order to circumvent laws, specifically the Federal Analogue Act, banning the sale of these 
substances specifically for human consumption. 
 
A wide array of substituted cathinones has been reported to be sold and used. However, 
there are two specific ones that deserve some more attention, namely 4-MMC and 
MDMC. They are particularly interesting for several reasons. For one, they were amongst 
the first cathinones to be sold in this newly developed drug market infrastructure. 
Second, they are the ones which are the most favored by users, producing the best 
subjective effects (Sogawa et al., 2011; Winstock et al., 2011). Third, they are very close 
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Figure 2.2 The number of new psychoactive substances notified for the first time in the EMCDDA Early 
Warning System since May 2005. A distinction has been made between cathinones specifically and all other 
reported substances, including cannabinoids, phenethylamines, tryptamines, opioids and others. Adapted 
from the EMCDDA–Europol 2013 Annual Report on the implementation of Council Decision 
2005/387/JHA(EMCDDA, 2014a). 
 
 
structural analogues of METH and MDMA, respectively. Aside from the β-ketone group, 4-
MMC differs from METH only by the addition of a methyl group on the 4-position on the 
phenyl ring, while MDMC is direct β-keto analogue of MDMA.  
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Although 4-MMC and MDMC are now banned in many countries due to the rapid surge in 
popularity they enjoyed, the amphetamine ring and side chain offer countless possibilities 
for substitutions. Chemists quickly came up with a large number of different substituted 
cathinones with names such as buphedrone, brephedrone, DMMC (Fig 2.1) and countless 
others, in order to replace the substances which had been banned. The cat-and-mouse 
game between governments and grey market chemists, where one drug is banned while a 
new one is already being developed and brought to the market, continues until the 
present day. 
 
2.4 DA, 5-HT and NE systems 
 
The primary targets of most amphetamines are the DA, 5-HT and NE systems. This is 
perhaps not surprising, as all three of these systems belong to the monoamine system, 
meaning they employ transmitter molecules consisting of an aromatic ring connected to 
an amino group by a two-carbon side chain, and thus bear strong resemblance to the 
basic phenethylamine structure of amphetamines (compare Fig. 2.1 and 2.4/2.5). What 
follows is a brief overview of the anatomy and function of these three monoamine 
systems, as well as a summary of the biogenesis and metabolism of their respective 
neurotransmitter molecules.  
 
2.4.1 Neuroanatomy 
 
The primary projections of the NE, DA and 5-HT system are shown in Fig. 2.3.  
 
Dopamine – DA neuronal cell bodies are located in various parts of the brain and give rise 
to several projections: the nigrostriatal pathway, consisting of cell bodies located in the 
substantia nigra that send projections to the striatum; the mesocorticolimbic pathway, 
consisting of cell bodies in the VTA projecting  to the limbic system and cortex and a 
smaller tuberoinfundibular pathway from the hypothalamus to the pituitary (Björklund 
and Dunnett, 2007). The different DA pathways are involved in regulating separate brain 
functions. The nigrostriatal projection plays an important role in regulating movement 
while the mesocorticolimbic system controls many different aspects of motivation and 
cognition. The tuberoinfundibular pathway plays a role in prolactin secretion (DeLong, 
1990; Porter et al., 1990; Di Chiara, 1998; Floresco and Magyar, 2006) 
 
Serotonin – 5-HT neurons have cell bodies located in the raphe nuclei from which axonal 
projections travel upwards, similarly to NE axons, also via the medial forebrain bundle to 
form widespread synaptic contacts with targets in the cortex, basal ganglia, limbic system 
and hypothalamus (Sullivan, 1995). Serotonin plays an important role in several brain  
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Figure 2.3 Schematic drawing of the DA, 5-HT and NE systems in the human brain. The primary DA projections 
are the mesocorticolimbic and the nigrostriatal pathways. A smaller projection known as the 
tuberoinfundibular pathway (not shown) exists between the hypothalamus and pituitary gland and is involved 
in prolactin secretion. Projections of the 5-HT and NE systems originate in the raphe nucleus and locus 
coeruleus, respectively, and proceed upward via the medial forebrain bundle to numerous targets including 
the cortex, hippocampus and basal ganglia or downward into the spinal cord. 
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functions such as sleep, and the regulation of mood and appetite (Ursin, 2002; Halford et 
al., 2005; Martinowich and Lu, 2008) 
 
Norepinephrine – NE neuronal cell bodies are primarily located in the locus coeruleus. 
From here, axons travel upward in the medial forebrain bundle, forming connections 
throughout the cortex, hippocampus, (hypo)thalamus and cerebellum (Jones and Moore, 
1977). The locus coeruleus also sends projections downward to the spinal cord (Westlund 
and Coulter, 1980). The brain NE system plays an important role in regulating a number of 
brain functions including arousal, attention, memory and anxiety (Tanaka et al., 2000; 
Marzo et al., 2009). 
 
2.4.2 Neurotransmitter biogenesis and metabolism 
 
Catecholamines – The neurotransmitters DA and NE are both catecholamines, and their 
biosynthesis occurs in the same pathway (Fig 2.4). TH converts L-tyrosine to levodopa, 
which is subsequently converted to DA by aromatic amino acid decarboxylase. NE is 
produced from DA by dopamine-β-hydroxylase. DA is metabolized by MAO and catechol-
O-methyltransferase to produce HVA. NE is similarly metabolized by MOA and catechol-
O-methyltransferase to produce 3-methoxy-4-hydroxyphenylglycol and vanillylmandelic 
acid (Brady et al., 2011) 
 
Serotonin – The biosynthesis of 5-HT begins with tryptophan, which is converted by TPH 
to 5-hydroxytroptophan and subsequently converted by aromatic amino acid 
decarboxylase to 5-HT. The metabolism of 5-HT by MAO and aldehyde dehydrogenase 
yields the metabolite 5-HIAA (Fig. 2.5). Furthermore, a separate circadian rhythm-
dependent metabolic shunt exists in the pineal gland, through which 5-HT is converted to 
melatonin (Brady et al., 2011). 
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Figure 2.4 Overview of catecholamine biosynthesis and metabolism. The left row shows the synthesis of DA 
and NE from L-tyrosine. The rows to the right show the metabolism into their respective breakdown products. 
Arrows indicate enzymatic reactions and the name of the enzymes are given near the arrows.  
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Figure 2.5 Overview of 5-HT biosynthesis and metabolism. The top half of the figure shows the biosynthesis of 
5-HT from its precursor tryptophan. The bottom half of the figure shows the metabolism of 5-HT into 5-HIAA 
or melatonin (in the pineal gland). The arrows indicate enzymatic reactions performed by the enzyme listed 
next to the arrow. 
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2.5 Neuropharmacology of amphetamines 
 
Several decades of research have revealed many details about the neuropharmacology of 
amphetamines. Historically, the mechanisms that have received the most attention are 
the ability of AMPH to inhibit the reuptake and enhance the release of DA via the DAT, as 
well as its ability to promote the release of DA from secretory vesicles (Sulzer et al., 2005; 
Fleckenstein et al., 2007). The primary mechanisms of AMPH action in the nerve terminal 
are shown in Fig. 2.6. An overview of the main properties and neuropharmacological 
effects of amphetamines is provided in Table 2.1.  
 
Unraveling the pharmacological action of AMPH has been a century-long endeavor and is 
in many ways an extension of even earlier work on the effects of epinephrine. In early 
work, British physician George Oliver discovered that adrenal gland extract would 
increase blood pressure when he injected it into his son’s radial artery. The discovery that 
the vassopressive action was due to the presence of epinephrine gave rise to the theory 
of secretory transmission: the idea that nerves communicate via the excretion of 
chemical messengers. Subsequently, it was discovered that also other substances, such as 
AMPH, could produce a similar effects as epinephrine, and these substances were termed 
sympathomimetics, due to their ability to mimic the effects of the sympathetic nervous 
system. In the 1950’s, experiments with reserpine demonstrated that some 
sympathomimetics, such as epinephrine, were capable of contracting blood vessel even 
after reserpine treatment, whereas other sympathomimetics, such as AMPH, where not. 
Thereby the discovery of the distinction between directly and indirectly acting drugs - the 
latter being dependent on the presence of an intact sympathomimetic system acting by 
releasing epinephrine-like substances - was made (Burn and Rand, 1958; Sulzer et al., 
2005). 
 
Recently it has become clear that, aside from inhibiting reuptake and enhancing release 
of neurotransmitter via reuptake transporters, AMPH is also capable of modulating action 
potential-dependent neurotransmitter release (Branch and Beckstead, 2012; Daberkow 
et al., 2013). Furthermore, AMPH regulates DA neurotransmission via a number of 
mechanisms and also has an array of targets outside the DA system (Fung and Uretsky, 
1982; Robinson, 1985; Ritz and Kuhar, 1989; Matsumoto et al., 2014; Reese et al., 2014). 
Many of these targets have been identified only recently, and their importance in 
mediating the physiological, behavioral, therapeutic, reinforcing and toxic effects of 
AMPH is just beginning to be understood. Nonetheless, it is now clear that amphetamine 
action is much more complex and extends far beyond the mechanisms which have 
traditionally received the most attention.  
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Drug property or effect Section Brief description 
AMPH vs. METH 2.5.1 - The subjective effects of the drug are similar and neither drug 
appears more addictive than the other.   
- Subtle differences exist between AMPH and METH as AMPH 
releases more DA in the PFC.  
- Due to their similar pharmacological action the drugs will be 
considered interchangeable here. 
D- and l-isomers 2.5.1 D-AMPH appears to be a more potent DA releaser than L-AMPH and 
produce stronger behavioral effects such as locomotor activity. 
Action at the 
plasmalemmal DAT 
2.5.2 - AMPH prevents reuptake of DA by competitive inhibition of DAT. 
- AMPH releases DA by reversing the direction of DAT and inducing 
transient channel-like states during which DA is transported 
outwards 
Regulation of DAT surface 
expression 
2.5.2.2 - The effects of AMPH are determined by DAT surface expression 
and function, which is regulated by PKC/CaMKII phosphorylation and 
ROS signaling. 
- AMPH can target these mechanisms to regulate DAT surface 
expression. 
Modulation of exocytotic 
DA release 
2.5.3 - Recently it has become clear that AMPH also enhances exocytotic 
DA release. 
- The exact mechanism is unknown but could be related to the 
ability of AMPH to induce persistent transporter-mediated ion 
leakage and excitatory conductance.  
Effects on secretory 
vesicles 
2.5.4 - AMPH promotes the release of neurotransmitter from secretory 
vesicles.  
- Mechanisms include disruption of the vesicle membrane proton 
gradient as well as inhibition and internalization of VMAT-2.  
Regulation of TH and MAO 2.5.5.1 - AMPH reduces MAO function and can both increase and decrease 
TH activity. 
- Mechanisms include direct interaction with the feedback inhibition 
site or induction of phosphorylation at other regulatory sites. 
Outside the DA system 2.5.5.2 - In addition to DAT, AMPH also inhibits reuptake and enhances 
release of neurotransmitters via NET and SERT. 
- Recently, novel AMPH targets such as the σ receptor and trace 
amine associated receptor-1 have been identified that appear to 
play an important role in mediating the effects of AMPH. 
Substituted 
amphetamines 
2.5.6 - Substituted amphetamines and cathinones also inhibit reuptake 
and increase release of monoamines via transporters, but differ 
from AMPH in their relative preference for SERT, DAT and NET  
 
Table 2.1 The table lists the main neuropharmacological effects of AMPH together with a brief description 
and a reference to the sections in which the respective effects are discussed in further detail.   
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Figure 2.6 A graphical representation of some of the important actions of AMPH in the nerve terminal. AMPH 
is taken up by the DAT but also diffuses across the membrane. Inside the nerve terminal, it may enter 
synaptic vesicles, resulting in release of DA from the vesicles into the cytosol. Competitive reuptake inhibition 
and increased DA release lead to elevated synaptic DA levels and subsequent increases in the postsynaptic 
response. AMPH also activates numerous signalling pathways and enzymes, leading to cellular responses such 
as phosphorylation and internalization of DAT.   
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In this section, the current state of the art of amphetamine neuropharmacology is 
reviewed. First, the effects of AMPH at the plasmalemmal DAT and the complex 
mechanisms by which AMPH regulates DAT function will be discussed. Second, the effects 
on secretory vesicles will be discussed and third, other AMPH targets outside the DA 
system will be briefly mentioned. The section ends with a discussion about the 
neuropharmacology of substituted amphetamines and cathinones, and how their 
mechanism of action differs from that of AMPH. 
 
2.5.1 AMPH, METH and their isomers 
 
Prior to discussing the mechanism of amphetamine action in the nervous system, it is 
important to distinguish two slightly different drugs which both have been used for 
studying the pharmacological and neurochemical effects of amphetamines, namely AMPH 
and METH. These two substances, as well as their isomers, display subtle differences in 
terms of their pharmacology. Nonetheless, the notion that one of them is more powerful 
and addictive than the other has been hard to back up empirically. 
 
One study showed that equimolar concentrations of AMPH and METH evoke a similar 
amount of DA release in the striatum and show similar elimination rates (Melega et al., 
1995). Another study confirmed that the two substnaces produce similar increases in 
nucleus accumbens DA levels and actually found that AMPH increases PFC DA levels more 
than METH, while also producing a higher peak locomotor activity (Shoblock et al., 
2003b). In line with the effect on PFC DA levels, it was discovered that AMPH has a 
stronger effect than METH on working memory function. The effects of AMPH and METH 
on working memory are bimodal, with a small dose increasing performance while higher 
doses produce a decrease. For AMPH, a dose of 0.5 mg/kg (doses calculated based on 
free base weight) increased working memory performance whereas a 2 mg/kg dose 
decreased it. METH, on the other hand, had little effect at 0.5 mg/kg, produced the 
highest increase at 2 mg/kg and a decreased performance only at 4 mg/kg (Shoblock et 
al., 2003a).  
 
In terms of subjective effects, AMPH fully substitutes for METH in animals trained to 
discriminate METH from placebo (Desai and Bergman, 2010) and also causes dose-
dependent increases in METH-appropriate responding in humans taught to discriminate 
10 mg METH from placebo (Sevak et al., 2009), suggesting that also the subjective effects 
are very similar, if not indistinguishable. Moreover, it was shown that varying doses 
(between 12 and 50 mg intranasally) of AMPH or METH produce similar subjective effects 
and did not differ from each other with regards to the rate at which participants would 
opt for a cash reward instead of a dose of the drug (Kirkpatrick et al., 2012), thereby not 
corroborating the notion that METH is more addictive or reinforcing than AMPH.  
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Both AMPH and METH exist as isomers with subtle differences in their neurochemical and 
behavioral properties. For AMPH, the d-isomer appears to be a more potent DA releaser, 
whereas the l-isomer is an equally or more potent releaser of NE (Heikkila et al., 1975; 
Holmes and Rutledge, 1976; Mendelson et al., 2006). Furthermore, the d-isomers of 
AMPH and METH appear more potent than the l-isomers in producing behavioral effects 
such as locomotor activity, self-administration and taste aversion (Balster and Schuster, 
1973; Yokel and Pickens, 1973; Carey and Goodall, 1974; Segal, 1975). Illicit METH is 
usually distributed as either a racemic mixture of d- and l-isomers or as pure d-isomer, 
depending on the method of synthesis most prevalent at the time (Logan, 2002; 
Mendelson et al., 2006) 
 
In scientific literature, by tradition, work on the mechanism of action of amphetamines is 
primarily done with AMPH, whereas studies on neurodegeneration and toxicity 
preferentially employ METH (Sulzer et al., 2005). However, since these substances seem 
to show more similarities than differences, the assumption will be made here that results 
and conclusions from experiments employing AMPH can be generalized to METH, and 
vice versa, in order to better integrate literature from these two overlapping fields.   
 
2.5.2 Action of AMPH at the plasmalemmal DAT 
 
The DAT, together with the NET and SERT, belong to the solute carrier-6 gene family of 
secondary-active transporters consisting of 12 transmembrane domains as well as 
intracellular domains with phosphorylation and binding sites that are vital for its 
regulation. Normally, the transporters depend on a pre-existing concentration gradient of 
Na+ and Cl- to co-transport one molecule of Na+ together with one neurotransmitter 
molecule from the extracellular space into the cytoplasm (Robertson et al., 2009). 
 
The ability of AMPH to increase extracellular DA levels in regions such as the nucleus 
accumbens is well-established (Carboni et al., 1989; Pierce and Kalivas, 1995; Pontieri et 
al., 1995). Early studies already demonstrated that AMPH inhibits the reuptake of DA via 
the DAT (Parker and Cubeddu, 1988). However, intracytoplasmic injections of AMPH also 
increase extracellular DA, and this effect is blocked by the competitive DAT inhibitor 
nomifensine, indicating that AMPH, aside from blocking the reuptake, also enhances the 
release of intracellular DA (Sulzer et al., 1995; Tatsumi et al., 1997). It was also shown that 
the uptake of radiolabelled AMPH into striatal synaptosomes is a saturable, high-affinity, 
ouabain-sensitive (ouabain blocks the plasmalemmal Na+/K+ ATPase) and temperature-
dependent process, suggesting that AMPH is itself transported into the cell via the DAT as 
a substrate (Zaczek et al., 1991). This notion was supported by a study employing cells 
transfected with human DAT, which confirmed that AMPH elicited voltage-dependent 
inward currents that were Na+ dependent, ouabain-sensitive and inhibited by the DAT 
blocker cocaine (Sitte et al., 1998). Although it is clear that AMPH blocks the reuptake of 
DA and is taken up via the DAT as a substrate, it is important to note that AMPH is a 
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lipophilic weak base (Mack and Bonisch, 1979; Gulaboski et al., 2007) which will readily 
diffuse through the plasma membrane and enter the cytoplasm independently of the 
DAT. Thus, entry of AMPH into the cytoplasm is not dependent on the presence of DAT.  
 
2.5.2.1 Mechanisms of DAT-mediated DA release 
 
Exchange-diffusion 
 
Although it is clear that AMPH releases DA via the DAT, it raises the question by which 
mechanism this occurs. The early exchange-diffusion model (Fischer and Cho, 1979) 
stated that AMPH, like DA, would bind the extracellular binding site, producing a 
conformational change in the DAT protein resulting in the binding site traversing the 
membrane, releasing AMPH into the cytoplasm and simultaneously binding a DA 
molecule which would then be transported outwards. This model implied that the 
exchange was limited to one molecule of AMPH exchanging for one molecule of DA. 
Although it is possible that this type of exchange does take place it has become clear that 
exchange-diffusion is not limited to 1:1 ratio of AMPH exchange for DA. This is evidenced 
by the fact that intracytoplasmic injections of AMPH also induce DAT-mediated DA efflux 
without AMPH first being taken up by the DAT, as mentioned above. Moreover, the DAT 
can be regulated, as discussed below, via intracellular second messengers to switch 
between “reluctant” and willing” states for AMPH-mediated DA efflux without affecting 
inward transport (Khoshbouei et al., 2004). 
 
Channel-like transport 
 
Next to the exchange-diffusion mechanism of DA release, AMPH is also capable of 
producing rapid bursts of DA release via the DAT. This is indicative of AMPH causing a 
conformational change to the DAT that result in a channel-like state, in which DA is 
rapidly transported outward via a pore in the transporter protein. The channel 
phenomenon is transient, consisting of millisecond bursts, and is inhibited by the 
presence of DA on both sides of the plasma membrane, and therefore not capable of 
transporting DA against its concentration gradient (Kahlig et al., 2005).  
 
2.5.2.2 Regulation of DAT function and surface expression 
 
The ability of AMPH to induce DAT-mediated DA release is considered one of its most 
important properties. However, this ability is highly dependent on the degree of DAT 
function and surface expression on the plasma membrane. These parameters are 
controlled by several intracellular messenger systems which are described below. 
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PKC phosphorylation 
 
PKC is a serine/threonine kinase that plays an important role in regulation of DAT function 
and surface expression. It exists in a number of different isotypes which can be divided 
into the classical isotypes that are activated by Ca2+ and diacylglycerol and includes the α, 
βI/II and ɣ isotypes. A second group known as the novel PKC isotypes is not activated by 
Ca2+, but requires only diacylglycerol. This group includes the isotypes, ε, and δ. Finally, a 
third group referred to as the atypical PKC isotypes are insensitive to both Ca2+ and 
diacylglycerol, and includes the isotypes ζ and λ (Mellor and Parker, 1998; Olive and 
Messing, 2004). Unfortunately, selective PKC modulators have not been used in many 
studies(Mochly-Rosen et al., 2012), and therefore not much can be concluded about the 
influence of specific isotypes of PKC on DAT regulation. 
 
PKC-activating and phosphatase-inhibiting drugs both decrease the uptake of DA into 
striatal synaptosomes. The effect is inhibited by the PKC inhibitor staurosporine and does 
not affect total DAT-binding (Copeland et al., 1996; Zhang et al., 1997). Studies in striatal 
synaptosomes employing [32P]orthophosphatase to assess the amount of DAT 
phosphorylation confirmed that phosphorylation of intracellular DAT-domains is 
regulated by PKC, and that the degree of DAT phosphorylation is negatively correlated to 
the efficacy of DA uptake (Vaughan et al., 1997). These results may be explained by the 
fact that PKC activation removes DAT from the membrane to endosomes, whereas PKC 
inhibition promotes the insertion of DAT into the membrane, something which has been 
confirmed using immunofluorescent confocal microscopy (Pristupa et al., 1998; Sorkina et 
al., 2003).  
 
In addition to affecting DA uptake, PKC-mediated DAT phosphorylation also affects 
AMPH-induced DA release. One study found that PKC-inhibiting drugs almost completely 
inhibited AMPH-induced DA efflux, while increasing baseline DA uptake without the 
presence of AMPH (Kantor and Gnegy, 1998). DAT proteins with mutations of serine to 
alanine on N-terminus, the main target of PKC phosphorylation, show a strong reduction 
of AMPH-induced DA release (Khoshbouei et al., 2004; Foster et al., 2012). The effects of 
PKC-mediated DAT phosphorylation thus appear to affect both baseline DA uptake as well 
as AMPH-induced DA efflux. However, whereas increases in phosphorylation appear to 
decrease the efficacy of baseline DA uptake, the opposite appears to be the case for 
AMPH-mediated DA efflux, which is enhanced by phosphorylation.  
 
Exposure to METH induces DAT phosphorylation both in vivo and in vitro (Cervinski et al., 
2005) and, furthermore, even a single injection of METH in vivo rapidly (within 1 h) and 
reversibly decreased plasmalemmal DA uptake, without affecting total binding of the 
membrane permeable DAT ligand [3H]WIN35428, indicative of METH-induced transient 
receptor internalization or loss of function (Fleckenstein et al., 1997c; Kokoshka et al., 
1998). The loss of surface DAT following AMPH was also directly confirmed using 
microscopy in human DAT-expressing cells (Saunders et al., 2000). These data suggest 
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that AMPH produces transporter internalization in a similar way as PKC activation does. 
However, there appear to be subtle differences between PKC-mediated and AMPH-
mediated DAT internalization. First, although AMPH-induced DAT internalization is clearly 
observed in vitro , it  has been difficult to show in vivo, as even repeated AMPH or METH 
treatment do not appear to cause DAT internalization in the same way as the PKC-
activating drugs do, but still produce a decrease in synaptosomal DA transport, suggesting 
the DAT is close to the membrane, but not functioning normally (German et al., 2012). 
Recent work may offer an explanation for these results as it was shown that both AMPH 
and PKC activation result in loss of cell surface DAT in vitro. However, contrary to the PKC-
induced internalization, which was dependent on ubiquitination of the transporter and 
subsequent sorting to lysosomes for degradation, the AMPH-induced internalization 
sorted DAT to recycling endosomes (Hong and Amara, 2013), likely destined for rapid re-
insertion into the cell membrane.  
 
CaMKII phosphorylation 
 
AMPH-mediated DA efflux appears to be influenced also by CaMKII. This kinase binds the 
DAT at the distant C terminus and, similarly to PKC, phosphorylates N-terminal serine 
residues, leading to enhanced AMPH-induced DA efflux. Mutations of DAT N-terminal 
serines to alanines which inhibit phosphorylation block this enhancement, demonstrating 
that both CaMKII and PKC increase AMPH-induced DA efflux via phosphorylation of the 
same serine residues present in the first 22 DAT N-terminal amino acids (Granas et al., 
2003; Fog et al., 2006). CaMKII appears to influence AMPH-induced DA efflux via the DAT 
through Syntaxin A1, a SNARE protein which, aside from being involved in synaptic vesicle 
release, also interacts with and regulates transmembrane proteins, including DAT. Cells 
overexpressing Syntaxin A1 show an increased AMPH-mediated DA efflux and this effect 
is blocked by CaMKII inhibition, suggesting a model were binding of CaMKII at the C-
terminal leads to subsequent phosphorylation of N-terminal residues which in turn 
promote binding of Syntaxin A1 to DAT and leading to the facilitation of AMPH-mediated 
DA efflux (Binda et al., 2008; Robertson et al., 2009). Interestingly, association of Syntaxin 
A1 with the DAT is also subject to regulation by AMPH itself (Binda et al., 2008), pointing 
to another target by which AMPH regulated its own effects at the DAT. 
 
ROS signaling 
 
Finally, aside from regulation of DAT directly via kinase-mediated phosphorylation there 
is also evidence suggesting that ROS signaling may be involved in regulating cell surface 
DAT expression (Fleckenstein et al., 2007). The oxygen radical generating enzyme 
xanthine oxidase reduces DA uptake into striatal synaptosomes, an effect inhibited by co-
application of the free radical scavenger superoxide dismutase (Berman et al., 1996; 
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Fleckenstein et al., 1997b). As discussed in more detail below, AMPH is also capable of 
generating ROS, so also this regulatory pathway is open to modulation by AMPH itself.  
 
Regulation of DAT function via phosphorylation and ROS are some mechanisms by which 
DAT surface expression and function is regulated. As these mechanisms are affected by 
the presence of AMPH itself, it appears that the final amount of DA released into the 
synapse in response to AMPH depends on a complex interplay between AMPH and 
intracellular second messenger systems. To add to this complexity, it has more recently 
become clear that AMPH can induce DA release via mechanisms independent of the DAT 
as well. 
 
2.5.3 AMPH-mediated modulation of exocytotic DA release 
 
Although non-exocytotic release via DAT-mediated reverse transport was long considered 
the primary mechanism by which AMPH increases extracellular DA levels, this claim has 
been challenged recently, as evidence mounts that AMPH also affects action potential-
dependent DA release. One study which examined this demonstrated that AMPH, at 10 
mg/kg, enhanced electrically evoked DA release measured within 30 minutes after the 
injection. Additionally, a low dose (1 mg/kg) of AMPH facilitated the DA release 
associated with a rewarding stimulus cue, suggesting that AMPH acts, at least in part, by 
altering the characteristics of action potential-dependent exocytotic DA release 
(Daberkow et al., 2013). The exact mechanism by which AMPH enhances the Ca2+-
dependent release of DA is unknown, but it may be related to the ability of AMPH to 
induce persistent transporter-mediated ion-leakage and excitatory conductance (Ingram 
et al., 2002; Branch and Beckstead, 2012; Rodriguez-Menchaca et al., 2012).  
 
Thus, in addition to inhibiting the reuptake and enhancing the release of DA via the DAT, 
AMPH also enhances action potential-dependent vesicular DA release. The interplay 
between these mechanisms is responsible for the final behavioral and neurochemical 
effects of AMPH, and the relative importance of these mechanisms can be affected by 
several factors. It has been suggested that reuptake inhibition is primarily associated with 
lower drug concentrations corresponding to those in the therapeutic range, whereas 
doses in the recreational range shift the primary mechanism to DA release (Calipari and 
Ferris, 2013). Furthermore, there appear to be region-specific changes in the relative 
importance of DAT-dependent and action potential-dependent DA release, with 
enhancement of vesicular release being more important in the dorsal striatum compared 
to the ventral striatum (Avelar et al., 2013). 
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2.5.4 Effects of AMPH on secretory vesicles 
 
In addition to releasing DA from the cytoplasm to the extracellular space, AMPH also 
promotes the release of DA from secretory vesicles into the cytosol. Several mechanisms 
by which AMPH can induce release of DA from secretory have been suggested, including 
AMPH weak base effects and direct interactions with the vesicular monoamine 
transporter 2 (VMAT-2). 
 
AMPH is a lipophilic weak base (Mack and Bonisch, 1979; Gulaboski et al., 2007), and as 
such, is capable of traversing the membranes of synaptic vesicles. The lumen of secretory 
vesicles is acidic, with a pH of around 5.5 (Mellman et al., 1986; Njus et al., 1986). Thus, 
once inside the vesicle lumen, AMPH is protonated, which decreases its membrane 
permeability and leads to accumulation of AMPH inside the vesicles. The protonation of 
AMPH also results in loss of the proton gradient established by the H+-ATPase across the 
vesicular membrane, which is required by the secondary active VMAT-2 transporter to 
sequester DA into the vesicles, and eventually leads to the release of DA into the 
cytoplasm (Sulzer and Rayport, 1990; Sulzer et al., 2005). The loss of DA from secretory 
vesicles is evidenced by a decrease in the quantal size due to the lower amount of DA in 
individual vesicles. However, after prolonged (6-48 hour) exposure to METH, a rebound 
hyperacidification and subsequent increase in quantal size has been reported (Markov et 
al., 2008), indicating the presence of homeostatic mechanisms capable of preventing 
long-term loss of DA from secretory vesicles. 
 
In addition to promoting release by interfering with the membrane proton gradient, 
AMPH has affinity for VMAT-2 itself, suggesting it may also interfere with the uptake of 
DA into vesicles. The competitive inhibition of vesicular DA uptake together with the 
ongoing leakage of transmitter from the vesicles would eventually also result in a net loss 
of vesicular DA levels (Sulzer et al., 2005). Finally, it has been shown that repeated high-
dose METH treatment decreases vesicular DA uptake without affecting total binding of 
the VMAT-2 ligand dihydrotetrabenazine, consistent with removal of VMAT-2 from the 
vesicular membrane (Brown et al., 2000; Hogan et al., 2000). Recent work with N-
terminally mutated VMAT-2 indicated the presence of phosphorylation sites involved in 
regulating, in similarity to the DAT N-terminus, METH-mediated DA efflux (Torres and 
Ruoho, 2014) and provides a possible mechanism involved in the regulation of VMAT-2 
membrane surface expression (Gonzalez et al., 1994; Fleckenstein et al., 2007).  
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2.5.5 Other AMPH targets 
 
2.5.5.1 Regulation of MAO and TH function 
 
In addition to its actions at the plasmalemmal DAT and secretory vesicles, AMPH also 
exerts influence on DA neurotransmission by other means. The ability of AMPH to block 
MAO has been repeatedly demonstrated both in vitro and in vivo (Mantle et al., 1976; 
Green and el Hait, 1978; Clarke et al., 1979; Miller et al., 1980; Robinson, 1985). 
Furthermore, AMPH also increases DA synthesis by enhancing TH function (Costa et al., 
1972; Kuczenski, 1975), although higher concentrations appear to decrease TH function 
(Kogan et al., 1976; Hotchkiss and Gibb, 1980). This highlights that AMPH, at least to a 
certain extent, compensates for its enhancement of DA efflux by increasing cellular DA 
levels through inhibiting DA breakdown and increasing DA biosynthesis. As part of a 
normal regulatory mechanism, TH is subject to feedback inhibition by catecholamines. 
Although the exact mechanism by which AMPH alters TH function is not known, it is 
possible that AMPH competes with catecholamines for this binding site without 
producing the same inhibitory effect. Additionally, several kinases, including CaMKII and 
protein kinase A, extracellular signal-related kinase and mitogen activated protein kinase 
can phosphorylate a range of TH serine residues and produce effects such as activation or 
alleviation of feedback inhibition (Daubner et al., 2011). Since it has been shown that 
AMPH exposure indeed results in phosphorylation of regulatory TH serine sites 
(Klongpanichapak et al., 2008), this mechanism is most likely involved in the regulation of 
TH function by AMPH.  
 
2.5.5.2 Outside the DA system 
 
Aside from increasing DA levels, AMPH also increases extracellular levels of 5-HT and NE 
(Kuczenski and Segal, 1997) in a similar fashion, namely by inhibiting the reuptake and 
enhancing the release of these neurotransmitters via their respective plasmalemmal 
transporters (Parada et al., 1988; Rothman et al., 2001; Hilber et al., 2005). The effects of 
AMPH in these other monoamine systems play an important role in mediating its 
behavioral effects (Sloviter et al., 1978).  
 
Several other AMPH targets are also known. Recently the trace amine associated 
receptor-1 (Reese et al., 2014) and σ receptor (Matsumoto et al., 2014) have received 
attention. The trace amine associated receptor-1 is a G-protein coupled receptor and co-
localizes with DAT in certain regions. It exerts a modulatory effect on monoamine 
neurotransmission (Xie and Miller, 2009), and therefore also plays an important role in 
mediating the action of amphetamines. The importance of this receptor is demonstrated 
by the fact that trace amine associated receptor-1 knock-out mice show clear behavioral 
differences and respond much more strongly to the locomotor activating and rewarding 
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effects of AMPH (Achat-Mendes et al., 2012). The σ receptor is another interesting target 
as recent data shows this receptor to play a key role in mediating METH neurotoxicity, 
with blockade of the σ receptor attenuating the striatal DA depletions, cytokine activation 
and cognitive impairments induced by high-dose METH treatments in rodent models 
(Robson et al., 2013a; Robson et al., 2013b; Seminerio et al., 2013). 
 
For AMPH and METH, the DA system is clearly important in mediating its neurochemical 
and behavioral effects, although it is clear that some of its effects are also mediated by 
different neurotransmitter systems, some of which only recently have been identified. 
Furthermore, once the amphetamine molecule is subjected to substitutions, its affinity 
for the different monoamine system changes in distinctive ways. 
 
2.5.6 Action of substituted amphetamines and cathinones 
 
The substituted amphetamines MDMA, 4-MMC and MDMC have a mechanism of action 
which is reminiscent of AMPH and METH, but differ in the ratio of their effects at various 
monoamine systems. As mentioned above, AMPH and METH, in addition to its action at 
the DAT, also display affinity for NET and SERT. However, both METH and AMPH show a 
strong preference for the catecholamine transporters, and have much lower affinity for 
the SERT (Nichols, 1994; Simmler et al., 2013). Subsequently, their main effect in vivo is to 
increase extracellular DA levels in the nucleus accumbens and frontal cortex without very 
pronounced effects on 5-HT release (Carboni et al., 1989; Melega et al., 1995; Shoblock et 
al., 2003b; Kehr et al., 2011) 
 
2.5.6.1 MDMA 
 
Substitutions on the phenyl ring on the amphetamine molecule produces compounds 
with much higher affinity for SERT, while in many cases maintaining some DA releasing 
properties as well (Nichols, 1994). Thus, the ring substituted amphetamine MDMA is a 
potent 5-HT releasing agent with relatively weak effects at the DAT (Cozzi et al., 1999; 
Verrico et al., 2007; Simmler et al., 2013). Thus, in vivo, it produces increases in both 5-HT 
and DA levels, but with 5-HT levels increasing more than those of DA (Kehr et al., 2011; 
Baumann et al., 2012). Furthermore, like AMPH and METH, MDMA also induces 
neurotransmitter efflux from secretory vesicles (Rudnick and Wall, 1992; Mlinar and 
Corradetti, 2003).  
 
2.5.6.2 4-MMC and MDMC 
 
The substituted cathinones 4-MMC and MDMC have similar affinity for plasmalemmal 
monoamine transporters as their non-keto analogues, but display a more than 10-fold 
lower affinity for the VMAT-2 transporter (Cozzi et al., 1999; Baumann et al., 2012; 
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Martinez-Clemente et al., 2012). The exact importance of the lower VMAT-2 affinity is 
currently unknown, however, since 4-MMC is a weak base (Santali et al., 2011) it is not 
unlikely that it is also capable of inducing neurotransmitter efflux from secretory vesicles 
in a similar way as non-keto amphetamines. In vivo, 4-MMC produces a neurochemical 
effect best described as somewhere in between MDMA and METH, producing large 
increases in both DA and 5-HT levels. Meanwhile, MDMC produces a neurotransmitter 
release pattern similar to but slightly weaker than MDMA, increasing primarily 5-HT levels 
(Kehr et al., 2011; Baumann et al., 2012; Wright et al., 2012b), but not as much as MDMA. 
 
In summary, the primary effect of amphetamines is to increase monoamine 
neurotransmission by inhibiting the reuptake and enhancing the release of the 
monoamines DA, NE and 5-HT. The monoamine release is dependent on a range of 
interactions between AMPH and cellular constituents such as second messenger systems, 
secretory vesicles and enzymes. Moreover, substitutions of the amphetamine molecules 
produce important changes in the relative affinity of the drugs for different monoamine 
systems, producing a wider possible range of effects. Amphetamines have been used for 
a long time, both for medical as well as recreational purposes. This raises the next 
question, namely whether amphetamines have any long-term neurotoxic effects on the 
brain that persist for long after the initial effects wear off. 
 
2.6 Evidence of amphetamine neurotoxicity 
 
2.6.1 Preclinical studies 
 
2.6.1.1 Studies suggesting structural toxicity 
 
The work on METH and MDMA neurotoxicity gained pace in the 1980s as the drugs 
gained popularity amongst recreational users. One study (Ricaurte et al., 1982) 
demonstrated that high doses of METH (3 injections of 50 mg/kg spaced over 8 hours) 
caused destruction of nerve terminals in the rat striatum as observed 4 days after the 
treatments using a silver staining method, considered the gold standard of neurotoxicity 
testing (Switzer, 2000). Furthermore, it was reported that similar regimens also reduced 
levels of DA and 5-HT in the striatum and other brain regions, such as the frontal cortex 
and amygdala (Ricaurte et al., 1980; Ricaurte et al., 1982). The observation that high 
doses of METH produce neurotoxicity, visible as swollen fibers and nerve terminals 
indicative of axonal damage has been confirmed by other investigators (Escalante and 
Ellinwood, 1970; Lorez, 1981). Recently, evidence of toxicity measured using silver 
staining was observed for METH even at lower doses (3x 5 mg/kg) (Ares-Santos et al., 
2014).  
 
36 
 
There is also evidence of structural damage to neurons after high doses of MDMA. For 
instance, one study reported axonal degeneration following 80 mg/kg MDMA twice daily 
for two days (Commins et al., 1987b). Another study where MDMA was administered 
twice daily for two days at doses between 25 and 150 mg/kg appears to show significant 
degeneration of axons at doses of 50 mg/kg and higher based on the presented graphs, 
although statistics are not presented (Jensen et al., 1993). Similar results were reported 
by Molliver et al. (1990) who administered MDMA (20 mg/kg twice daily for 4 days) and 
found evidence of structurally damaged axons which appeared as swollen stumps in 
cortical regions using silver staining. The axonal damage coincided with loss of fine axons 
5-HT immunoreactivity in cortical regions 2 weeks after treatment.  
 
2.6.1.2 Immunological and neurochemical studies 
 
Thus, it appears that high doses of both METH and AMPH can produce structural damage 
to neurons, which often coincides with decreases in levels of DA or 5-HT, or the levels of 
their respective transporters and synthesizing enzymes. A large body of evidence suggests 
that high-dose amphetamines produce alterations in the DA and 5-HT systems, such as 
decreases in DA and 5-HT levels, DAT and SERT binding and decreases in the levels and 
activity of the synthesizing enzymes TH and TPH, after various dosing regimens and 
survival intervals. 
 
METH 
 
In rodents, numerous studies demonstrate that METH can affect 5-HT and DA axons. For 
instance, METH produces axons that appear swollen and varicose, reminiscent of what is 
seen with silver staining, and display a decrease in 5-HT immunoreactive boutons (Fukui 
et al., 1989). Similarly, both METH and AMPH were reported to produce reductions in TH-
positive neurons in the caudate nucleus and frontal cortex, with AMPH also producing 
swollen and enlarged axons (Kadota and Kadota, 2004; Bowyer and Schmued, 2006).  
 
Quantitative ligand-binding and neurochemical methods also suggest alterations in 
monoamine systems following METH. Numerous studies have reported decreases in 
striatal DA and 5-HT levels following treatment with METH, with at least partial recovery 
occurring over time (Wagner et al., 1980; Seiden et al., 1988; O'Dell et al., 1991; Cass, 
1996; Callahan et al., 1998; Cass and Manning, 1999). Also DAT and SERT levels, as 
measured by ligand-binding or uptake measurements, are decreased following METH 
(Hirata and Cadet, 1997; Brown et al., 2000; Ladenheim et al., 2000; Schroder et al., 2003; 
Armstrong and Noguchi, 2004). Finally, decreases in the levels and function of the 
synthesizing enzymes TH and TPH have been reported, also with recovery occurring as 
the survival interval increases (Hotchkiss and Gibb, 1980; Bakhit et al., 1981; Haughey et 
al., 1999; Schroder et al., 2003). 
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MDMA 
 
MDMA appears to have an effect on 5-HT axons, but not on DA axons, in rats. For 
instance, decreased 5-HT positive neurons were observed in the parietal cortex and 
forebrain regions following treatment with high doses of MDMA, and similar to METH, 
the remaining axons were ablated or thick and varicose. However, no damage was 
observed to the cell bodies in the raphe nucleus or to catecholaminergic neurons. 
Furthermore, the loss of 5-HT axons recovered to a large extent after one year (O'hearn 
et al., 1988; Molliver et al., 1990; Scanzello et al., 1993). 
 
The loss of 5-HT immunoreactivity, as expected, coincides with loss of 5-HT and SERT-
binding in brain regions including the cortex, striatum, hippocampus and hypothalamus. 
Also decreases in TPH function have been reported. The alteration of these markers 
commonly recovers with time. Further, the alterations are limited to the 5-HT system, 
and no studies report any alterations in the catecholaminergic systems in rats (Stone et 
al., 1986; Battaglia et al., 1987; Battaglia et al., 1988; Souza et al., 1990; Sprague et al., 
1994; Armstrong and Noguchi, 2004).  
 
Notably, MDMA appears to produce pronounced differences in its toxicity profile 
depending on what species is used for testing. In mice, even very high doses of MDMA 
(60 mg/kg) do not affect 5-HT system markers such as brain 5-HT or TPH activity levels 
(Stone et al., 1987), but instead decrease DA levels, particularly in the striatum (Logan et 
al., 1988; O'Callaghan and Miller, 1994). 
 
Studies in non-human primates 
 
Studies in rhesus monkeys, vervet monkeys and baboons support the plasticity profile 
observed in rats, with METH decreasing DA as well as DAT and VMAT-2 binding in various 
brain regions such as the striatum and cortex, but with recovery occurring over time 
(Woolverton et al., 1989; Melega et al., 1997; Villemagne et al., 1998; Hashimoto et al., 
2004). Meanwhile, MDMA affects only the 5-HT system, as observed by decreased levels 
of 5-HT and SERT binding as well as loss of 5-HT positive axons in brain regions including 
cortical regions and the hippocampus, again with at least partial recovery occurring as the 
time between the drug treatments and the measurements increases (Insel et al., 1989; 
Souza et al., 1990; Hatzidimitriou et al., 1999). 
 
It seems clear that high doses of METH and MDMA can induce consistent and long-term 
alterations to the brain DA and 5-HT systems in several species. This raises the question if 
these alterations have any significance in terms of their effect on important brain 
functions, such as those related to cognition, anxiety and mood. 
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2.6.1.3 Long-lasting cognitive and behavioral effects of amphetamines 
 
In rodents, cognition and neurobehavioral function can be assessed using a range of 
animal behavioral tests. Examples include memory tests such as the novel object 
recognition test and the Morris water maze, tests of anxiety-like behavior in emergence 
tests, elevated plus maze tests and social interaction tests as well as the forced swim test, 
said to measure aspects of depression (McGregor et al., 2003a; Clemens et al., 2004; 
Clemens et al., 2007).  
 
METH 
 
METH was shown to decrease recognition memory in the novel object recognition test for 
up to several weeks after drug treatments (Schroder et al., 2003; Marshall et al., 2007; 
Herring et al., 2008). Also decreases in spatial memory have been observed using tests 
such as the radial arm maze and Morris water maze (Nagai et al., 2007; Camarasa et al., 
2010). However, other studies report no effect on memory using the novel object 
recognition test (Clemens et al., 2007). Further, inconsistent results are obtained for 
anxiety-related behavior depending on the type of test used, and no effect was found on 
the forced swim test (Clemens et al., 2004; Clemens et al., 2007). 
 
MDMA 
 
With MDMA, the evidence of persistent long-lasting effects on rodent behavioral tests is 
also difficult to interpret. Evidence of decreased memory performance has been reported 
using a variety of behavioral paradigms (Marston et al., 1999; Mechan et al., 2002; Piper 
and Meyer, 2004), as have increases in anxiety and depressive-like behavior using such 
tests as the elevated plus maze, emergence test, social interaction test and forced swim 
test (McGregor et al., 2003a; McGregor et al., 2003b). However, decreases in anxiety 
after MDMA has been observed using these same tests (Mechan et al., 2002; Piper and 
Meyer, 2004), and also memory deficits following MDMA are not always observed 
(McGregor et al., 2003b). In fact, some studies found no evidence of impairment in 
MDMA-treated animals tested on a wide range of behavioral tests, including memory 
tests such as the radial arm maze and the Morris water maze, despite the fact that large 
decreases in cortical 5-HT levels were present (Seiden et al., 1993; Marston et al., 1999), 
indicating that the relationship between observed monoamine system deficits and 
functional outcome in terms of behavior and cognitive function is not straightforward.  
 
In summary, the effects of amphetamines on outcomes related to behavioral measures of 
cognition and neuropsychiatric function are inconsistent. Although alterations in tests 
measuring aspects of memory are sometimes reported, this is also by far the most 
studied outcome measure, where type I errors and publication bias may well produce a 
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skewed picture. The inconsistency may also suggest that the measured effects are not 
causally related to neurotoxicity but rather reflect changes in behavior due to stress 
associated with non-contingent high-dose drug treatments.  
 
2.6.2 Human studies 
 
A number of different types of studies and study designs have been used to assess the 
effects of amphetamines in humans. Most commonly, these studies employ 
neuroimaging, cognitive testing or, ideally, a combination of these. Certain studies have 
even examined post-mortem brain tissue of amphetamine users. Unfortunately, the 
cross-sectional design employed in most of these studies do not allow for firm 
conclusions to be drawn about causality of the observed effects (see also 6.6.1). 
 
2.6.2.1 Neuroimaging 
 
Positron emission tomography and SPECT 
 
Positron emission tomography and SPECT have been used to assess brain monoamine 
ligand binding and metabolism in human METH users. In analogy to what is seen in 
animals, these studies also show evidence of monoaminergic deficits, such as decreased 
DAT and VMAT-2 availability, as evidenced by decreases in [11C]WIN-35,428 and 
[11C]dihydrotetrabenazine binding in brain regions including the striatum and frontal 
cortex (McCann et al., 1998b; Sekine et al., 2001; Johanson et al., 2006). Metabolic 
positron emission tomography studies with [18F]fluorodeoxyglucose suggest that METH 
users show altered resting state or cognitive task-dependent metabolic activity in 
numerous cortical and subcortical brain regions which sometimes, but not always, is 
associated with lower cognitive performance or increases in neuropsychiatric symptoms 
such as anxiety and depression (Volkow et al., 2001a; London et al., 2004; Kim et al., 
2005; London et al., 2005; Kim et al., 2009) 
 
In abstinent MDMA users, the findings from positron emission tomography and SPECT 
studies also generally appear to support what is seen in preclinical studies. Abstinent 
MDMA users show decreases in binding of the SERT ligands [11C]-McN5652 and [11C]DASB 
in brain regions including the cortex, thalamus, hypothalamus and caudate nucleus. 
Additionally, abstinent MDMA users perform worse on tests of memory function, and 
their performance on these tests is correlated with the SERT-binding observed in the 
insula and hippocampus (McCann et al., 1998a; Kish et al., 2010). However, a study 
employing SPECT to assess [123I]beta-CIT  binding to SERT found a decrease only in 
recently abstinent female, but not male, MDMA users. Furthermore, in this study, the 
decreases in binding appeared to recover with protracted abstinence and in fact reached 
a level higher than control subjects in the group of subjects with prolonged abstinence 
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from MDMA (Reneman et al., 2001). In addition to changes in SERT-binding, decreased 
metabolism has also been reported with [18F]fluorodeoxyglucose positron emission 
tomography in regions such as the cingulate, hippocampus and amygdala and striatum, 
however, no correlation was found between metabolism and the amount of MDMA 
consumed (Obrocki et al., 1999; Buchert et al., 2001). 
 
Structural MRI 
 
Both structural and functional MRI studies have reported differences between METH 
users and non-users. It has been reported that abstinent METH users have lower gray 
matter density in the frontal cortex as well as decreased cognitive task performance 
compared to drug-free control subjects (Kim et al., 2006). Another study found decreased 
cingulate and hippocampal volumes that correlated with performance on a verbal 
memory test (Thompson et al., 2004). Correlations between increased METH exposure 
and reductions in the volume of the prefrontal cortex have also been described 
(Daumann et al., 2011). Interestingly, striatal volume is reportedly increased in abstinent 
METH users in a study which, however, did not find any evidence of decreased cognitive 
performance (Chang et al., 2005). Another study found increased putamen volume in 
METH users that correlated negatively with impulsivity scores (Jan et al., 2012). 
Decreased cortical and hippocampal volumes have also been reported in MDMA users 
(Cowan et al., 2003; den Hollander et al., 2012) 
 
Functional MRI 
 
Functional MRI studies also have reported differences in amphetamine users, such as 
decreased activity in the cingulate and prefrontal cortex of METH users that correlated 
with higher impulsivity scores (Monterosso et al., 2007; Hoffman et al., 2008). Decreased 
activation was also observed in frontal and insular cortex of METH users while performing 
a Stroop task, although actual task performance was not consistently decreased (Salo et 
al., 2009; Nestor et al., 2011). In MDMA users a weaker signal while performing a working 
memory task was noted in the frontal and temporal cortex in heavy compared to light 
users. However, when comparing users to non-users, there was no clear effect. 
Furthermore, task performance was also similar between MDMA users and controls 
(Daumann et al., 2003). Conversely, another study reported an increased signal in the 
frontal cortex in response to a memory task, on which MDMA users also were not 
impaired (Moeller et al., 2004). Similarly, hippocampal signal intensity in response to 
episodic or associative memory tasks revealed alterations in MDMA users versus controls, 
and in continuing versus abstinent MDMA users. However, also here no differences were 
observed on the actual task performance (Daumann et al., 2005; Becker et al., 2013). 
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2.6.2.2 Effects on cognition, mood and anxiety 
 
Some studies suggest that abstinent METH users show decreases in measures of cognitive 
function. Deficits in abstinent METH users compared to control subjects have been 
observed on tests such as immediate and delayed recall and digit span tests, which 
measure performance on memory-related domains, such as verbal memory, long-term 
declarative memory and working memory. Furthermore, deficits are also observed on 
tests such as the Wisconsin card sorting test, Stroop test and trail-making test, indicating 
deficits also in the cognitive domains of executive function and attention (Simon et al., 
2000; Kalechstein et al., 2003; Han et al., 2008; Rendell et al., 2009). Furthermore, METH 
users appear to experience higher levels of anxiety and depression than non-users 
(Zweben et al., 2004; Vik, 2007). 
Similar to METH, abstinent MDMA users also show deficits in certain cognitive domains. 
Also here, the most common observations include deficits in short term and long term 
memory, verbal reasoning, attention and executive functions as well as decreased 
performance in tests reflecting aspects of general intelligence (Parrott et al., 1998; 
McCann et al., 1999; Gouzoulis-Mayfrank et al., 2000; Heffernan et al., 2001; von Geusau 
et al., 2004). Other studies of abstinent MDMA users have also reported higher ratings of 
depression and anxiety in addition to decreases in memory performance (McCardle et al., 
2004; Thomasius et al., 2006).  
 
The main issue with these studies is that drug users and non-users are often not properly 
matched in terms of age, education, IQ and other relevant variables. In an attempt to 
minimize these confounding factors one study recruited all participants from the same 
demographic group (rave attendees). Furthermore, drug testing at the time of the 
neuropsychological evaluation was used to exclude subjects acutely under the influence 
of any substances. Here, no evidence was found of any consistent deficits in MDMA users. 
MDMA users showed lower vocabulary scores, but since these are usually not affected by 
neurological insults they were interpreted as a pre-existing difference (Halpern et al., 
2011). The lack of consistent results highlights the difficulty in interpreting cross-sectional 
studies and has led to a number of attempts at gaining more insight into actual drug-
dependent effects through a prospective study design.  
 
2.6.2.3 Prospective studies 
 
The first large prospective cohort study of MDMA users was done in The Netherlands. 
Subjects who were considered to be at high risk of commencing MDMA were recruited 
for an in-depth set of neuroimaging experiments at the time of recruitment, prior to using 
MDMA, and during a follow-up within 3 years. Individuals who started using MDMA 
showed decreased cerebral blood flow in the globus pallidus and putamen and decreased 
fractional anisotropy in thalamic and cortical white matter, compared to subjects who did 
not use MDMA. Importantly, however, no difference was observed between groups on 
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the most important outcome measure, namely SERT binding. A dose-response 
relationship between SERT binding and cumulative MDMA use was also not present (de 
Win et al., 2008). Cognitive function was also assessed. Those who started using MDMA 
scored significantly lower on immediate and delayed verbal recall compared to subjects 
who did not. Nonetheless, scores were within the normal range, and no effects were 
observed on any other neurocognitive tests. Most importantly, the verbal memory scores 
of MDMA users did not decrease, as the difference between groups was in fact due to an 
increase in performance of the non-users during follow-up (Schilt et al., 2007; Krebs and 
Johansen, 2008). 
 
Another prospective study also assessed MDMA-naïve subjects at baseline and during a 
follow-up after 12 months. Subjects were tested on a wide range of neurocognitive tests. 
Like in the Dutch study, no effects were found on verbal memory or other measures of 
neurocognitive function, with significant differences between groups being reported only 
for immediate and delayed visual memory. Here, the difference was indeed due to a 
decreased performance in the MDMA users, whereas the performance of individuals who 
stayed MDMA-naïve remained stable (Wagner et al., 2013). 
 
2.6.2.4 Studies on post-mortem tissue 
 
Aside from neuroimaging and cognitive studies in amphetamine users, analysis have also 
been made of post-mortem brain material and a decrease in striatal DA, DAT and TH 
levels have been reported in the brains of subjects who had used METH (Wilson et al., 
1996). Also a decrease in D1 receptor-mediated stimulation of adenylyl cyclase in 
response to DA has been reported (Tong et al., 2003), suggesting alterations both in the 
level and function of DA-related proteins in the brains of METH users. However, since the 
brains in these studies are likely sourced from individuals who died as a result of a METH 
overdose, their relevance for normal recreational users must be questioned.  
 
In summary, studies examining amphetamine users and non-users appear to show certain 
differences in brain function, such as decreases in monoamine transporter binding, 
metabolism and MRI signal intensities. Other studies also suggest decreased memory 
performance, but it remains difficult to interpret the results from these studies, due to 
inherent limitations of the study designs. Nonetheless, a large body of literature suggests 
that amphetamines have some long-term effects. A number of subsequent studies have 
attempted to outline what mechanisms may be involved in producing these effects.  
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2.7 Mechanisms of amphetamine neurotoxicity 
 
A number of mechanisms are thought to play a role in amphetamine neurotoxicity. The 
four mechanisms which have received the most are oxidative stress, mitochondrial 
dysfunction, excitotoxicity and hyperthermia. Additionally, a number of other processes, 
including inflammation and blood-brain barrier disruption have been implied to play a 
role. Also other neurotransmitter systems, such as the cannabinoid system and σ 
receptors, are now thought to play a role in mediating amphetamine neurotoxicity 
(Yamamoto et al., 2010; Achat-Mendes et al., 2012; Goncalves et al., 2014; Halpin et al., 
2014; Matsumoto et al., 2014). The proposed mechanisms are summarized in Table 2.2 
and discussed in more detail below.  
 
 
Mechanism Section Brief description 
ROS and oxidative stress 2.7.1 - Oxidative stress is a major contributor to amphetamine 
neurotoxicity. 
- Sources of ROS include (semi-)quinones from DA as well as 
reactive drug metabolites 
Mitochondrial dysfunction 2.7.2 - Amphetamines can inhibit specific complexes of the 
mitochondrial ETC. 
- The subsequent decrease in ATP production may produce 
energy deficits. 
- Inhibition of mitochondrial complexes results in electron 
leakage and production of the superoxide radical. 
Excitotoxicity 2.7.3 - A number of excitotoxic processes mediate amphetamine 
toxicity. 
- Activation of Ca2+-dependent enzymes such as xanthine 
oxidase, nitric oxide synthase and calpain causes production 
of superoxide and peroxynitrite and can initiate proteolysis of 
cytoskeletal protein. 
 
Hyperthermia 2.7.4 - Amphetamines increase core body temperature. Further 
increasing body temperature by administering the drug in 
high ambient temperature exacerbates toxicity while 
preventing hyperthermia attenuates toxicity. 
- Hyperthermia may catalyze the rate at which other toxic 
processes proceed. 
Other mechanisms 2.7.5 - A number of other mechanisms have been suggested to be 
involved in amphetamine toxicity. 
- Examples include inflammation, defects in the ubiquitin 
proteasomal system, blood-brain-barrier disruption and 
altered neurogenesis.  
 
Table 2.2 The table lists the primary mechanisms proposed to be involved in amphetamine neurotoxicity as 
well as a brief description of each mechanism and a reference to the section where they are discussed in 
more detail.   
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2.7.1 ROS and oxidative stress 
 
ROS are highly reactive molecules that can easily react with numerous biomolecules, 
including cellular lipids, proteins and DNA. This reaction leads to alteration of their 
composition or conformational structure, thereby rendering the affected molecules 
incapable of performing their normal functions. The damaging reactions between ROS 
and cellular constituents are known as oxidative stress. (Balasubramanian et al., 1998; Du 
and Gebicki, 2004; Catala, 2009).  
 
There are several types of oxidative stress. Protein oxidation refers to ROS forming 
covalent bonds with amino acids, for instance at the sulfur atom present on cysteine, 
thereby posing a threat to a vast number of proteins (LaVoie and Hastings, 1999). Lipid 
peroxidation is the process by which radicals oxidize cellular lipids. Particularly 
polyunsaturated fatty acids, such as those in cellular membranes, are vulnerable to 
oxidation. Aside from damaging membranes and other cellular constituents, the products 
of lipid peroxidation, such as hydroxy-2-nonenal, resulting from the oxidation of fatty 
acids, are themselves reactive, and can initiate adduct formation with other biomolecules 
such as proteins and ribonucleic acids (Sprague and Nichols, 1995; Yamamoto and Zhu, 
1998; Gluck et al., 2001; Catala, 2009), resulting in further damage. 
 
2.7.1.1 Sources of amphetamine-induced ROS 
 
Some of the major pathways of reactive species generation as a result of amphetamines 
are summarized in Fig. 2.7. One of the major sources of increased oxidative stress 
following amphetamines is the large increase in cytoplasmic and extracellular DA levels, 
and the subsequent metabolism of DA into toxic metabolites (Yamamoto and Raudensky, 
2008). DA can be both enzymatically and non-enzymatically metabolized, and both routes 
can result in the production of reactive products. DA can be by MAO, resulting in the 
production of 3,4-dihydroxyphenylacetaldehyde, the transient precursor of 3,4-
dihydroxyphenylacetic acid (DOPAC), and hydrogen peroxide. When glutathione is 
incapable of detoxifying all the hydrogen peroxide, it may react with Fe2+ in a Fenton 
reaction, resulting in the production of the hydroxyl radical OH•. Moreover, both DA and 
3,4-dihydroxyphenylacetaldehyde can undergo auto-oxidation to form DA- or 3,4-
dihydroxyphenylacetaldehyde-(semi)quinones (Sulzer and Zecca, 2000; Anderson et al., 
2011). Both OH• and DA-(semi)quinones are highly reactive species, capable of reacting 
with a plethora of different biomolecules (LaVoie and Hastings, 1999; Munoz et al., 2012) 
 
Other potential sources of ROS are amphetamine metabolites themselves. Particularly 
MDMA has been implied as a source of reactive metabolites. The catechol-like hepatic 
metabolites of MDMA, 3,4-dihydroxymethamphetamine (HMMA) and 3,4-
dihydroxyamphetamine (HHA) are thought to be capable of auto-oxidizing, much like DA 
itself. The resulting quinones are highly reactive and could easily form thioether  
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Figure 2.7 Overview of important pathways for generation of reactive species. Major sources of reactive 
species are DA, reactive metabolites of amphetamines, oxygen in the mitochondria and excitotoxic processes 
(in black boxes). The reactions leading to reactive species (marked in red) are indicated by thick arrows. DA 
metabolism produces reactive DA-quinones and hydrogen peroxide which may lead to production of hydroxyl 
radicals. The transient DA metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL) can form 3,4-
dihydroxyphenylacetaldehyde -quinones. In mitochondria, electrons escaping the electron transport chain 
may reduce oxygen, producing superoxide while excitotoxic processes, which increase Ca2+ levels, may 
produce additional superoxide via activation of enzymes such as xanthine oxidase. Increased nitric oxide 
synthase (NOS) activity elevates nitric oxide, which can react with superoxide to produce peroxynitrite. These 
reactive species may damage cellular lipids, proteins and DNA. Furthermore, lipid peroxidation may itself 
produce reactive products which cause further damage. 
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conjugates with sulfur-containing compounds such as glutathione and N-acetyl-cysteine. 
These thioether compounds retain the ability to redox cycle and are toxic to 5-HT 
neurons. In fact, they are more toxic than MDMA itself (Monks et al., 2004; Ferreira et al., 
2013). Evidence supporting this pathway comes from detection of the abovementioned 
adducts in vivo (de la Torre and Farre, 2004; Perfetti et al., 2009).  
 
Finally, another very important reactive species is superoxide (O2-). Superoxide is 
produced, for instance, during DA oxidation. Moreover, a number of other enzymes 
produce superoxide during their normal functioning. However, another  important source 
of amphetamine-induced superoxide production is the mitochondrion (see section 2.7.2). 
 
2.7.1.2 Role of oxidative stress in amphetamine toxicity 
 
Support for the involvement of oxidative stress as a causal mechanism in amphetamine 
toxicity comes from a number of studies demonstrating attenuation of METH-induced 
monoamine loss with antioxidants such as N-acetyl-cysteine, ascorbic acid, vitamin E and 
selenium (Wagner et al., 1985; De Vito and Wagner, 1989; Fukami et al., 2004; Barayuga 
et al., 2013). Further, both METH and MDMA were found to increase the production of 
OH•, and pre-treatment with spin trapping agents or antioxidants attenuated the long-
term monoamine depletions normally observed after these amphetamines (Colado and 
Green, 1995; Yamamoto and Zhu, 1998; Shankaran et al., 1999). Accordingly, depletion of 
glutathione, inhibition of superoxide dismutase and the feeding of a selenium-deficient 
diet all increase the toxicity observed after MDMA and METH (De Vito and Wagner, 1989; 
Sanchez et al., 2003; Chandramani Shivalingappa et al., 2012).  
 
2.7.1.3 Factors mediating ROS production 
 
DA 
 
As mentioned in the beginning of this section, DA is an important factor in amphetamine-
induced ROS production. Further evidence for this comes from the fact that blockade of 
DAT and inhibition of DA synthesis both reduce the METH-induced loss of DA, 5-HT or TPH 
activity (Schmidt et al., 1985; Marek et al., 1990; Yamamoto and Zhu, 1998). Additionally, 
the potent electron transport chain inhibitor 6-hydroxydopamine has been observed in 
the brain following METH treatment and are thought to also be a result of oxidation of DA 
by OH• (Seiden and Vosmer, 1984; Commins et al., 1987a; Glinka et al., 1997; Wrona et 
al., 1997). Oxidative stress following METH, as measured by lipid peroxidation and protein 
oxidation, was significantly decreased in PKCδ knockout mice or mice treated with the 
PKCδ-inhibitor rottlerin. These mice also did not show any METH-induced alterations in 
TH, DAT and VMAT-2 function. Since inhibitors of other PKC isoforms had no effect, these 
results suggest a specific role of the PKCδ isoform in mediating METH-induced oxidative 
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stress (Shin et al., 2012). These data are particularly interesting considering the role of 
PKC-mediated phosphorylation in enhancing AMPH-induced, DAT-mediated DA efflux 
(see section 4.3.2.2). 
 
DA in MDMA toxicity 
 
Less obvious may be that DA also plays a role in mediating MDMA toxicity, as this drug 
exerts less effect on DA neurotransmission than METH. Nonetheless, MDMA-induced 
decreases in 5-HT were potentiated by levodopa administration, while inhibition of DA 
synthesis protected against decreases in 5-HT and TPH function (Stone et al., 1988; 
Schmidt et al., 1990). Moreover, the DAT blocker mazindol decreased the amount of 
MDMA-induced production of OH• and loss of 5-HT and TPH function, while knockdown 
of MAO-B using by antisense oligonucleotides attenuated the loss of 5-HT levels in the 
striatum (Shankaran et al., 1999; Falk et al., 2002), indicating an important role of DA 
oxidation in mediating the toxic effects of MDMA. It has been even shown that MDMA 
increased tyrosine levels in the hippocampus and that administration of extra tyrosine 
enhanced, while administration of an aromatic amino acid decarboxylase-inhibitor 
decreased, MDMA-induced 5-HT depletion. These results suggest a mechanism whereby 
levodopa, following enzyme-independent hydroxylation from tyrosine, is converted to DA 
by aromatic amino acid decarboxylase (Breier et al., 2006), and demonstrate that DA may 
play a role in MDMA toxicity even in brain regions very sparsely innervated by DA, such as 
the hippocampus.  
 
Excitotoxicity 
 
A number of additional sources of amphetamine-induced oxidative stress are related to 
excitotoxicity, and are discussed in more detail in section 2.7.3. 
 
2.7.2 Mitochondrial dysfunction 
 
Amphetamines can inhibit specific complexes of the mitochondrial ETC, resulting in 
increased levels of ROS and deficits in energy production (Fig. 2.8). METH and MDMA are 
known to decrease the levels and activity of mitochondrial complexes I, II and IV in the 
striatum (Burrows et al., 2000a; Brown et al., 2005; Klongpanichapak et al., 2006; Puerta 
et al., 2010). MDMA was also shown to cause deletions in mitochondrial 
deoxyribonuncleic acid coding for subunits of complexes I and IV following a two week 
survival interval (Alves et al., 2007). More recently it was shown that even relatively low 
doses of both AMPH and METH (2mg /kg or less) decrease complex I, II or IV activity in 
various brain regions, including the striatum, frontal cortex and amygdala in tissue 
obtained from animals sacrificed while still under the influence of the drug (Feier et al., 
2012).   
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Figure 2.8 The figure shows the mitochondrial ETC which consists of complex I (NADH dehydrogenase), 
complex II, (succinate dehydrogenase), complex III (ubiquinone-cytochrome c reductase), complex IV 
(cytochrome c oxidase) and complex V (ATP synthase). METH and MDMA are known to inhibit several 
mitochondrial complexes, including I, II and IV. The resulting breakdown of the normal productive electron 
flow through the mitochondrial complexes (marked by yellow lightning strikes next to the electrons), 
necessary to produce the electrochemical H+ gradient needed for ATP production, results in increased leakage 
of electrons from the ETC (red arrows from complexes I and III), where they readily react with molecular 
oxygen. The subsequent superoxide production can exceed the capacity of superoxide dismutase (SOD) and 
glutathione (GSH) (again marked with yellow lightning strikes), resulting in increased production of 
superoxide and ROS, as well as a cellular energy deficit due to the inhibited ATP production. Figure adapted 
from Li et al. (2013). 
 
 
Inhibition of the mitochondrial ETC by amphetamines can result in reduction of ATP levels 
following impairment in oxidative phosphorylation, as well as increases in oxidative stress 
due to excessive leakage of superoxide from the collapsed ETC. It has even been 
suggested that amphetamine-induced mitochondrial dysfunction may cause apoptosis. 
 
2.7.2.1 Failure of ATP production and cellular energy deficit 
 
It is known that METH decreases ATP and oxygen levels in the striatum and cortex while 
increasing AMP levels (Shiba et al., 2011). The role of decreased ATP levels in 
amphetamine toxicity is demonstrated by an experiment where neural glucose uptake 
was prevented by administration of 2-deoxyglucose, a manipulation that enhanced both 
the decrease in ATP levels observed directly after METH treatment as well as the loss of 
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striatal DA one week later (Chan et al., 1994). Similarly, inhibition of metabolism by 
directly interfering with the ETC also increases toxicity. For instance, the complex II 
inhibitor malonate exacerbated METH-induced depletions of striatal DA levels (Burrows 
et al., 2000b). Similarly, malonate decreased both 5-HT and DA levels after a 5 day 
survival interval at a dose of MDMA which did not produce any reductions in the levels of 
these transmitters on its own (Darvesh et al., 2005). One cannot conclude with certainty 
that the effects on monoamine levels are due to decreased ATP, as the toxicity may also 
have been exacerbated due to oxidative stress resulting from ETC inhibition (see below).  
 
However, since application of the energy substrates decylubiquinone or nicotinamide 
attenuated the METH-induced loss of striatal DA after 7 days, it is likely that it does play a 
role, particularly as this effect was only present when the substrates were infused 6 hours 
following METH administration, but had no effect when they were administered together 
with METH (Stephans et al., 1998), suggesting that the protective effects were mediated 
by increasing ATP levels in the time following METH treatment. Deficient energy 
metabolism may have important consequences. Aside from producing monoaminergic 
toxicity, it has even been suggested that METH-induced neurotoxicity occurring from 
bioenergetics failure in brainstem regions may be directly responsible for cardiovascular 
collapse occurring with lethal METH doses, as it was shown that co-treatment with 
coenzyme-Q10 in the medulla prevented both superoxide production and death (Li et al., 
2012).  
 
2.7.2.2 Superoxide leakage and increased oxidative stress 
 
Aside from reducing ATP levels, ETC inhibition can also exacerbate amphetamine toxicity 
by increasing oxidative stress. During normal mitochondrial functioning, large amounts of 
electrons are transported through the ETC, eventually leading some electrons to escape 
and react with molecular oxygen to form superoxide, the primary reactive species in 
mitochondria. During normal oxidative phosphorylation it is estimated that about 1-4% of 
mitochondrial oxygen will be reduced to superoxide. However, when mitochondrial  
 
complexes are inhibited and the existing electron flow through the complexes is blocked, 
the electron leak and subsequent superoxide production will increase dramatically. 
Normally, the amount of superoxide dismutase, glutathione and catalases present in 
mitochondria is sufficient to detoxify the produced superoxide, but the increased electron 
leakage following amphetamine-mediated ETC inhibition may outrun the capacity of 
detoxification enzymes, leading to the generation of other reactive species such as OH• 
and subsequent damage to cellular components. The exact source of electron leakage 
from within the ETC following inhibition from METH and MDMA is hard to predict, as it 
depends on several factors, including mitochondrial substrate utilization status and which 
specific complexes are inhibited, however, it is clear that any inhibition of mitochondrial 
complexes will increase ROS production (Adam-Vizi, 2005). The result is clear, as the ROS 
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production, which is already increased following amphetamines, will be further enhanced 
due to increased mitochondrial ROS (Brown and Yamamoto, 2003), thereby further 
increasing the likelihood of oxidative stress-mediated toxicity.  
 
2.7.2.3 Apoptosis 
 
Finally, the mitochondrial-dependent apoptotic pathway has also been suggested to play 
a role in amphetamine toxicity (Cadet et al., 2005). METH increases the expression of pro-
apoptotic genes such as BAD, BAX and BID, while decreasing the expression of anti-
apoptotic genes Bcl-2 and Bcl-XL (Jayanthi et al., 2001; Krasnova et al., 2005; Beauvais et 
al., 2011). Indeed, METH has been shown to trigger the release of apoptosis inducing 
factor, cytochrome c and smac/DIABLO from the mitochondria to the cytoplasm, leading 
to the recruitment of caspases and initiation of apoptotic cell death (Jayanthi et al., 2004). 
Both overexpression of Bcl-2 and inhibition of caspases, protects against METH toxicity 
(Cadet et al., 1997; Uemura et al., 2003). It is important to note that this effect has 
primarily been observed following very high doses of METH or in vitro, and the in vivo 
relevance remains unclear (Cadet et al., 2003). 
 
2.7.3 Excitotoxicity 
 
Excitotoxicity is the process by which excessive stimulation of glutamate receptors leads 
to influx of toxic levels of Ca2+ into neurons. All types of glutamate receptors, including 
the metabotropic glutamate receptors, have been implicated in the process of 
excitotoxicity, but the N-methyl-D-aspartate (NMDA) receptor is considered to be the 
primary mediator, due to the high capacity of its ion channel for Ca2+ transport. The high 
levels of intracellular Ca2+ lead to number of downstream processes such as 
depolarization of the mitochondrial membrane potential, activation of Ca2+-dependent 
enzymes including nitric oxide synthase and PKC (primarily the classical Ca2+-dependent 
isoforms α, βI/II and ɣ have been associated with excitotoxicity), as well as the activation 
of various phospholipases, phosphatases and proteases such as calpain and caspases 
which can have potentially detrimental effects on cellular components including 
mitochondria, endoplasmatic reticulum, cytoskeletal proteins and DNA, and may 
eventually cause cell death via apoptosis or necrosis (Buchner et al., 1999; Mark et al., 
2001; Arundine and Tymianski, 2003; Dong et al., 2009; Lee et al., 2014).  
 
2.7.3.1 Glutamate receptor involvement 
 
Studies employing in vivo microdialysis have shown that METH increases glutamate 
release in the striatum (Nash and Yamamoto, 1992; Stephans and Yamamoto, 1994; Mark 
et al., 2004), and that blockade of metabotropic glutamate receptors attenuates METH-
induced depletion of striatal DA and other markers of toxicity (Battaglia et al., 2002; Shah 
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et al., 2012), indicating that aspects of excitotoxicity play a role in METH toxicity. NMDA 
receptor blockade using dizocilpine also attenuates METH toxicity (Farfel et al., 1992; 
Bowyer, 1995). However, since NMDA receptor antagonism also decreases METH-induced 
hyperthermia, it is impossible to determine whether the protective effects are due to 
attenuation of excitotoxicity-mediated aspects of toxicity or if it is a general protective 
effect mediated by the attenuation of hyperthermia (see below). Furthermore, the NMDA 
antagonist amantadine apparently increases, rather than attenuates, the toxicity of METH 
and this demonstrates that NMDA receptor antagonism is not always sufficient to prevent 
METH toxicity. Importantly, amantadine also produces actions besides NMDA receptor 
antagonism that may influence its effects of amphetamine toxicity (Ossola et al., 2011; 
Thrash-Williams et al., 2013).  
 
2.7.3.2 Intracellular excitotoxic processes 
 
The increases in intracellular Ca2+ activates downstream processes that lead to further 
increases in ROS production and to the activation of Ca2+-dependent proteases, both of 
which can damage cellular components. 
 
Excitotoxicity-mediated ROS production 
 
The METH-induced glutamate release and subsequent increases in intracellular Ca2+ may 
lead to increased ROS production in several ways. Increased Ca2+ leads to activation of 
enzymes such as calpain and xanthine oxidase. Xanthine oxidase catalyzes the conversion 
of xanthine to uric acid in a process that also produces superoxide. Also Ca2+-dependent 
activation of phospholipase A2, which cleaves membrane phospholipids and releases 
arachidonic acid, may result in production of superoxide, following lipoxygenase- and 
cyclooxygenase-mediated metabolism of arachidonic acid (Yamamoto and Raudensky, 
2008).  
 
Another enzyme dependent on Ca2+ that is elevated during METH treatments is nitric 
oxide synthase, which catalyzes the conversion of arginine to nitric oxide. NO can readily 
react with superoxide to produce peroxynitrite (ONOO- ), a highly reactive anion of the 
reactive nitrogen species class. Like ROS, it readily reacts with a range of biomolecules 
and its targets include lipids, proteins as well as DNA (Pacher et al., 2007). Peroxynitrite 
produces toxicity through nitrosylation, the addition of nitric oxide to proteins, in 
particular to tyrosine and cysteine residues. Direct evidence for its involved in METH 
toxicity comes from data showing that METH-induced depletion of DA is accompanied by 
increased levels of striatal nitrate and nitrotyrosine, indicative of nitrosative toxicity 
(Anderson and Itzhak, 2006; Wang et al., 2008). Furthermore, blockade of nitric oxide 
synthase provides full protection against METH-induced loss of DA (Itzhak and Ali, 1996) 
while co-administration of a peroxynitrite decomposition catalyst together with METH 
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partially prevents toxicity (Imam et al., 1999). Even specific target proteins have been 
identified, as METH-induced nitrosylation coupled with loss of function has been 
observed on the VMAT-2 protein (Eyerman and Yamamoto, 2007). 
 
Activation of proteases 
 
Another event associated with excitotoxicity and increased intracellular Ca2+ levels is 
proteolysis of the cytoskeletal proteins, such as spectrin, by the Ca2+-activated enzyme 
calpain (Lee et al., 1991). Spectrin proteolysis has been observed in the rat striatum 
following METH treatments, while METH- and MDMA-induced increases in calpain 
activation and spectrin proteolysis were blocked by the calpain inhibitor calpastatin in 
vitro (Staszewski and Yamamoto, 2006; Warren et al., 2007; Suwanjang et al., 2012).  
 
The involvement of glutamate receptors as well as downstream mechanisms such as 
spectrin-mediated proteolysis of cytoskeletal proteins and increased nitric oxide synthesis 
and nitrosative stress clearly indicate that excitotoxic, Ca2+-dependent mechanisms play 
an important role in mediating METH toxicity. Nonetheless, the fact that the NMDA 
receptor antagonist amantadine exacerbated rather than attenuated METH toxicity 
indicates that there are still some unresolved questions regarding the exact role of 
excitotoxicity within the whole picture of amphetamine toxicity. 
 
2.7.4 Hyperthermia 
 
Hyperthermia plays a well-established and important role in mediating the toxicity of 
amphetamines. For instance, when METH is administered in a cold environment, the 
depletion of striatal DA levels is strongly attenuated. Moreover, the body temperature of 
individual animals is correlated to striatal DA levels and other measures of neurotoxicity 
(Ali et al., 1994; Bowyer et al., 1994). Ambient temperatures have a similar effect on the 
5-HT deficits observed after MDMA administration (Goni-Allo et al., 2008). In general, it 
seems that low ambient temperatures reduce, whereas high ambient temperatures 
increase, the neurotoxic effects of amphetamines (Broening et al., 1995; Malberg and 
Seiden, 1998).  
 
Alteration of body temperatures by means other than modulating ambient temperature 
similarly influences the effect of amphetamines on monoamine levels. For instance 
hypophysectomized or thyroparathyroidectomized rats, which do not develop 
hyperthermia in response to MDMA, are more resistant to the 5-HT neurotoxicity 
(Sprague et al., 2003). Pharmacological induction of hypothermia with drugs including 
diazepam and haloperidol also protect against depletion of brain monoamine levels 
(Bowyer et al., 1994). 
 
53 
 
Several neurotransmitter systems are involved in mediating the hyperthermic effects of 
METH. As discussed above, NMDA receptor antagonism reduces METH-induced 
hyperthermia and toxicity (Sonsalla et al., 1991; Farfel et al., 1992). However, a host of 
other receptors are also involved in modulating METH-induced hyperthermia. For 
instance, blockade of receptors including the DA D1, D2 and D3 receptors; the α1-
adrenoreceptor; the 5-HT2 receptor as well as the σ and orexin-1 receptor, all block or 
reduce METH-induced hyperthermia. Furthermore, the suppression of hyperthermia is 
associated with significant protection against METH toxicity (Doyle and Yamamoto, 2010; 
Seminerio et al., 2011; Ares-Santos et al., 2012; Rusyniak et al., 2012; Seminerio et al., 
2012; Kikuchi-Utsumi et al., 2013; Robson et al., 2013a; Sabol et al., 2013; Baladi et al., 
2014). Conversely, trace amine associated receptor 1-knockout mice exhibit slightly 
quicker response to the hyperthermic effects of METH and MDMA (Panas et al., 2010). 
 
The effect of body temperature on METH toxicity appears to depend on a specific 
interaction, as hyperthermia on its own does not deplete striatal DA levels (Bowyer, 
1995). It has been suggested to be due to a general effect on the enzymatic and non-
enzymatic reactions that are involved in amphetamine toxicity. For instance, it has been 
observed that hypothermia prevents METH-induced ROS production and oxidative stress 
(Fleckenstein et al., 1997a; Yamamoto et al., 2010) while hyperthermia, as expected, 
significantly increases ROS production and other measures of toxicity (Silva et al., 2013).  
 
2.7.5 Other factors 
 
In addition to oxidative stress, mitochondrial dysfunction, excitotoxicity and 
hyperthermia, a number of other mechanisms have been suggested to be involved in 
amphetamine toxicity as well. There is evidence of METH and MDMA-induced activation 
of microglia and subsequent increases in proinflammatory cytokines which can under 
some circumstances contribute to toxicity. Defects in the ubiquitin proteasomal system 
have also been reported and form an additional pathway affected by amphetamines 
which could have detrimental cellular effects. Furthermore, blood-brain-barrier 
dysfunction as well as interaction of amphetamine toxicity with factors such as stress and 
HIV-infections has been reported (Yamamoto et al., 2010).  
 
Alterations in neurogenesis in neurons derived from the subventricular zone 
stem/progenitor cells and the dentate gyrus have also been reported (Goncalves et al., 
2014). Further, toxic products such as ammonia, resulting from METH-induced damage to 
peripheral organs have also been suggested to play a role in mediating neurotoxic effects 
(Halpin et al., 2014).  
 
It is also becoming clear that amphetamine neurotoxicity is subject to regulation by a 
plethora of other systems and receptors including the CB1 and CB2 receptors, the trace-
amine associated receptor-1 and σ receptor which all play a modulator role in 
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monoamine neurotransmission and immune system function and microglial proliferation 
(Xie and Miller, 2009; Seminerio et al., 2013; Halpin et al., 2014). In many instances, these 
effects can be seen as downstream of, and dependent upon, the primary mechanisms of 
amphetamine toxicity described above. More details are available in recent reviews 
(Yamamoto et al., 2010; Goncalves et al., 2014; Halpin et al., 2014).  
 
The large body of evidence suggesting amphetamine-induced neurotoxicity due to 
processes related to ROS production, mitochondrial dysfunction, excitotoxicity and 
hyperthermia raise important questions regarding the potential toxicity of novel 
substituted amphetamines, such as the cathinones. 
 
2.8 Summary and rationale for the present study 
 
Although amphetamines have a long history of human use, it is only recently that there 
has been a strong increase in the use of completely new amphetamines, such as the 
substituted cathinones (Fig 2.2). The large increase in the prevalence of these substances 
is concerning because their lack of history of human use means virtually nothing is known 
about their safety or toxicity. This is particularly concerning in the case of the substituted 
cathinones, such as 4-MMC and MDMC, which are amongst the most popular new 
psychoactive substances and, furthermore, show a close similarity to METH and MDMA, 
drugs which are potentially neurotoxic to recreational users.  
 
The close similarity of the new substituted cathinones to well-known and potentially 
neurotoxic drugs, suggests that also the cathinones may produce similar neurotoxicity. 
Furthermore, the fact that the lifetime prevalence of illicit amphetamine use is over 10% 
in some countries (EMCDDA, 2014b), means that there are a large number of potential 
users for these new compounds, particularly as their apparent legality and relatively overt 
availability may lower the threshold for some people to try them. Therefore, a closer 
investigation of the potential toxicity of substituted cathinones, with a focus on 4-MMC 
and MDMC, is clearly warranted. 
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3. Aims of the study 
 
 
The aim of this thesis is to investigate whether β-keto amphetamines differ from their 
non-keto amphetamine analogues in terms of their long-term neuropharmacological 
effects and possible neurotoxicity, and to elucidate possible mechanisms responsible for 
any observed differences.  
 
The lifetime prevalence of recreational use of amphetamine-type stimulants is high, but 
most people use them infrequently and do not develop an addiction. In order to 
maximize the relevance of the obtained data, the studies were designed to answer the 
question of whether occasional binge-use of certain specific amphetamines or cathinones 
produces neurotoxicity or any other evidence of long-term neuropharmacological or 
neurophysiological effects. This information will provide valuable information for the 
development of an effective, evidence-based public health policy and harm reduction 
strategy.  
 
 
The aims of the specific studies were: 
 
I.  To investigate the possible differential susceptibility to MDMA-induced long-term 
alterations of the 5-HT system in human subjects and rat models between 
adolescence and adulthood. 
 
II.  To investigate the long-term effects of 4-MMC and MDMC on the monoamine 
system, cognitive function and other neurobehavioral tests using rat and mouse 
models. 
 
III.  To explore how 4-MMC and METH differ in terms of their long-term effects on 
brain activity and memory function in rats. 
 
IV.  To investigate possible mechanisms responsible for the observed similarities and 
differences between the effects of keto amphetamines and non-keto 
amphetamines in vitro. 
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4. Materials and methods 
 
This section briefly describes materials and methods used in more than one of the studies 
described below. Sections 4.2 – 4.6 provide an outline of materials and methods specific 
to the respective studies.  
 
Experimental animals – Male Wistar rats and C57BL/6 mice were used in these 
experiments. All animal experiments were performed according to relevant national and 
international guidelines and approved by the Animal Care Committee of The Academic 
Medical Center in Amsterdam or The Southern Finland Provincial Government. Drugs 
were dissolved in saline and administered intraperitoneally at a volume of 10 ml/kg for 
mice or 1 ml/kg for rats. Control groups were administered equal amounts of saline. 
 
Drugs and reagents – The cathinones used in these experiments were all obtained from 
the Hjelt Institute and, using gas chromatography and Fourier transform infrared 
spectroscopy, determined to be hydrochloride salts of ≥95% purity. Analytical grade 
METH hydrochloride was obtained from Sigma-Aldrich (St. Louis, MO, USA), D-AMPH 
sulfate from GlaxoSmithKline (Brentford, UK) and MDMA from THC Pharm GmbH 
(Frankfurt, Germany) and the Netherlands Forensic Institute (Rijswijk, The Netherlands). 
All other reagents used were analytical grade and obtained from Sigma-Aldrich, unless 
otherwise specified.  
 
Dosing regimen and dose selection – Drugs were administered twice daily for four 
consecutive days in order to mimic a long weekend of binge-use of a certain substance. 
Doses of AMPH and METH were selected to be in a similar range as those used in other 
studies (Bowyer et al., 1993; LaVoie and Hastings, 1999; Ossola et al., 2011). The 
substituted cathinones 4-MMC and MDMC were injected at a dose of 30 mg/kg. This dose 
was established in pilot experiments to produce a consistent 2°C increase in body 
temperature, similar to AMPH and METH, without producing lethality.  
 
Statistics – In all experiments statistical significance is assumed at p < 0.05 (2-tailed). 
 
4.1 Study I: Effect of age on MDMA neurotoxicity 
 
The effect of age on the susceptibility to MDMA neurotoxicity was assessed in both rats 
and humans. In a group of human MDMA users, the effect of age of first exposure to 
MDMA on SERT density was investigated using the radioactive ligand [123I]β-CIT in 
combination with SPECT neuroimaging. In parallel, the effect of age on MDMA 
neurotoxicity was assessed in rats by measuring the binding of this same ligand one week 
after treatment with MDMA in both adolescent and adult rats. This ligand has previously 
been validated and found to be well-suited for detecting alterations in SERT (Reneman et 
al., 1999). 
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4.1.1 SPECT imaging in humans 
 
4.1.1.1 Human subjects 
 
The population used in this study has been described previously (Reneman et al., 2001b; 
Reneman et al., 2001a). Subjects were recruited by means of flyers posted at venues 
associated with the “rave scene” in Amsterdam and with the help from Unity, an 
organization that provides information about drugs and harm-reduction at festivals and 
events. Data from 33 was reanalyzed and employed for this study. Exclusion criteria 
included presence of one or more lifetime psychiatric disorders (assessed by telephone 
interview prior to inclusion in the study) or a positive urine drug test at the time of the 
scan. The experiments were approved by the institutional Medical Ethics Committee of 
The Academic Medical Center in Amsterdam, and written informed consent was obtained 
from all participants. The study was conducted according to the principles expressed in 
the Declaration of Helsinki.  
 
4.1.1.2 SPECT imaging and data analysis 
 
For this study, subjects were divided into two groups based on the age at which they had 
first used MDMA. The first group consisted of subjects who had started using MDMA 
prior to age 18 (the early-exposure group, N=8), while the second group (the late-
exposure group, N=25) comprised subjects who had consumed MDMA for the first time 
after the age of 18. Subjects were administered approximately 140 millibecquerel [123I]β-
CIT and imaged 4 h later, at the time of maximum SERT binding. The brain-dedicated 
SPECT scanner (Strichman Medical Equipment 810X, Strichman Medical Equipment Inc., 
Medfield, Mass., USA) with a resolution of approximately 7.5 mm was used to acquire 
transversal slices in 5mm steps from the orbito-meatal line to the uppermost part of the 
head, producing acquisitions comprising approximately 15 slices each. The scanning time 
per slice was 3 min and the energy window was set to 135 – 190 KeV. 
 
An investigator blind to the experimental conditions performed a region of interest 
analysis for the frontal cortex, midbrain and the cerebellum using a standard template 
developed from co-registered MRI images. The binding in the cerebellum was used as a 
reference region as it is presumed to be low in SERT. The ratios of specific to non-specific 
binding were subsequently calculated by dividing the frontal cortical and midbrain 
binding by the binding observed in the cerebellum.  
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4.1.2 SERT binding studies in rats 
 
Rats (N=5-8 per group) were treated with MDMA (10 mg/kg, twice daily for four 
consecutive days) starting at either postnatal day 27 (adolescent) or 63 (early adulthood). 
Following a one week survival interval the animals were injected with [123I]β-CIT . Three 
hours later the animals were sacrificed by means of bleeding via heart puncture under 
carbon dioxide anesthesia and the brains were dissected into the following regions: PFC, 
temporal cortex, occipital cortex, hypothalamus, amygdala, hippocampus, striatum, 
cerebellum and superior colliculus. Subsequently, the radioactivity in each region was 
measured using a gamma counter. Binding of [123I]β-CIT to SERT was determined using 
the ratio of specific to non-specific binding using the cerebellum as a reference region 
(Reneman et al., 1999; van Dyck et al., 2000).  
 
4.1.3 Statistics 
 
In the SPECT experiment, differences in binding between the two groups were analyzed 
using the Student t-test while the association between age-of-first-exposure and SERT-
binding was analyzed using Spearman’s correlation coefficient and regression analysis.  
 
For the rat binding studies, group differences in SERT binding were analyzed using 
multivariate analysis of variance with age and treatment as independent variables, 
followed by Bonferroni post-hoc tests were appropriate. 
 
4.2 Study II: Long-term effects of 4-MMC and MDMC 
 
In order to investigate the potential neurotoxic effects of 4-MMC and MDMC, rats and 
mice were treated twice daily for four consecutive days with 4-MMC (30 mg/kg), MDMC 
(30 mg/kg) or AMPH (12.5 mg/kg) as a positive control. Two weeks after the final drug 
treatments, levels of monoamine neurotransmitters as well as DAT and SERT density was 
assessed using high-performance liquid chromatography and high-affinity radioligands. 
Behavioral tests were performed to assess the effects of these substances on memory 
function, anxiety and depressive behavior. One group of mice was used to measure brain 
monoamine levels while another group was used for behavioral experiments. Rat brains 
were used to measure monoamine levels as well as SERT and DAT binding. 
 
4.2.1 Measurement of monoamine levels 
 
Tissue levels of 5-HT, DA, NE, 5-HIAA, HVA and DOPAC in the PFC, striatum and 
hippocampus were measured using high-performance liquid chromatography with 
electrochemical detection. Brain samples from the frontal cortex, striatum and 
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hippocampus were prepared by sonication in 2% perchloric acid and centrifuged for 30 
min at 15,000×g after which 10 μl of filtered supernatant was injected into the high-
performance liquid chromatography system (Waters Concorde electrochemical detector, 
potential + 0.80 V, column oven and a 5 μm 150 × 4.60 mm column). The mobile phase 
was comprised of purified water with 8% methanol, 50 mM citric acid, 1.5 mM 1-
octanesulfonic acid, 0.05 mM ethylenediaminetetraacetic acid and 50 mM phosphoric 
acid. Column temperature was 37 °C with a flow rate of 1 ml/min. The retention times for 
NE, DOPAC, DA, 5-HIAA, HVA and 5-HT were 3.65, 5.47, 7.45, 9.16, 12.11 and 19.04 min, 
respectively. Concentrations of the neurotransmitters and metabolites were calculated 
from standard curves (linear from 10 nM to 1 μM).The lower limit of quantification was 
10 nM or 0.1 pmol/g of wet tissue. Samples were standardized based on wet weight. 
 
4.2.2 Measurement of DAT and SERT levels 
 
SERT binding in the hippocampus and DAT binding in the striatum were assessed using a 
filter-assay of [3H]paroxetine and [3H]mazindol binding to brain homogenates according 
to well-established methods (Battaglia et al., 1987; Hrdina et al., 1990; Robledo et al., 
2004; Chiu et al., 2007). Here, tissue samples were placed in a tube containing 10 ml 
incubation buffer (50mM Tris–HCl buffer with 120 mM NaCl and 5 mM KCl), and 
homogenized for 30 s with a Polytron. Tubes were centrifuged (48,000×g, 10 min) and 
then washed and resuspended to a volume of 15 mg wet weight/ml. Total [3H]paroxetine 
binding was assessed by incubation of the samples in tubes containing 4 nM 
[3H]paroxetine for 2 h at 22 °C. Non-specific binding was assessed in separate tubes by 
the addition of 20 μM citalopram to the incubation buffer in order to 
prevent[3H]paroxetine binding to SERT. Total [3H]mazindol binding was assessed by 
incubating the samples for 1 h at 4 °C in tubes containing 6 nM [3H]mazindol in the 
presence of 0.3 μM desipramine to block [3H]mazindol binding to NET. Non-specific 
binding was assessed in separate tubes by the addition of 100 μM nomifensine to the 
incubation buffer to block [3H]mazindol DAT binding. Following incubation, the tube 
contents were filtered through Whatman GF/B filters pre-soaked with 0.05% 
polyethylenimine and washed with 15 ml of buffer. Finally, the filters were placed in 
tubes and 3 ml Optiphase HiSafe 3 scintillation fluid was added (PerkinElmer, Turku, 
Finland). These were counted at 47% efficiency in a scintillation spectrometer.  
 
4.2.3 Behavioral experiments 
 
Memory function, anxiety, depressive behavior and locomotor activity were assessed 
using the T-maze and Morris water maze, the elevated plus maze, the tail suspension test 
and exposure to novel cages. Behavioral metrics were either recorded manually (at the 
time of the test or later using video recordings) or automatically using Ethovision 
software (Noldus Information Technology, Wageningen, Netherlands). 
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Working memory – the T-maze spontaneous alternation test was used to assess working 
memory (Gerlai, 1998; Linden et al., 2007). The maze consists of three arms with a door 
separating a 12 cm compartment of the start arm, and two other doors separating 24 cm 
compartments of the other arms. Spontaneous alternation was assessed by placing the 
mouse in the start arm and opening the door after 5 s to allow the mouse to visit either 
the left or right arm. After entering either arm, the opposite arm was closed. Every time 
the mouse returned to the start arm after entering either arm, it was confined for 5 s in 
the start arm, after which the doors were opened again. The total test time was 15 min. A 
higher rate of spontaneous alternation of arm visits is assumed to reflect better working 
memory.  
 
Spatial memory and reversal learning – spatial memory and reversal learning was 
assessed with the Morris water maze. Here, the rats were trained for 4 days (6 trials per 
day with a 10 min interval) to find a hidden platform (14 × 14 cm) submerged in a circular 
tub (120 cm diameter) filled with opaque water. On the 5th day, a probe trial was 
performed to assess the time taken to find the platform. The time the rat spent in each of 
the quadrants was also assessed. Lower latency to the platform and preference for the 
platform quadrant were interpreted as evidence of spatial memory. On day 6, reversal 
learning (5 trials with a 10 min interval) was performed by placing the platform in the 
opposite quadrant of the tub. Finally, on day 7, a second probe trial was performed to 
assess reversal learning.  
 
Anxiety – anxiety was measured using the elevated plus maze (Lister, 1987; Leppä et al., 
2011), in which the mouse is placed in a plus-shaped maze with 2 closed and 2 open arms 
(each arm 5 × 40 cm). A preference for closed arms over open arms was interpreted as 
evidence of anxiety.  
 
Depressive behavior – depressive behavior was assessed using the tail suspension test 
(Steru et al., 1985; Procaccini et al., 2011). In this test, increased immobility during a 6 
min tail suspension session is used as a measure of depressive behavior.   
 
Locomotor activity/habituation – Locomotor activity and habituation was assessed for 2 h 
after introduction of the animals to novel, empty cages.  
 
4.2.4 Statistics 
 
Data from transporter-binding, high-performance liquid chromatography and most 
behavioral experiments were analyzed using one-way analysis of variance with Fisher's 
least significant difference post-hoc tests or Kruskal–Wallis one-way analysis of variance 
and post-hoc pairwise comparisons. Data from the Morris water maze and locomotor 
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activity tests were analyzed by means of repeated measures analysis of variance with 
Greenhouse–Geisser correction. 
 
4.3 Study III: Effect of 4-MMC and METH on brain activity 
 
Since no clear long-term neurochemical effects of 4-MMC were observed in the previous 
study, an attempt was made to investigate the possible long-term neuropharmacological 
or neurophysiological effects of 4-MMC using MEMRI, a highly sensitive MRI method 
(Bangasser et al., 2013; Hoch et al., 2013). Following 4-MMC (30 mg/kg) or METH (5 
mg/kg) twice daily for four consecutive days, a MEMRI scan was performed on rats two 
weeks after the final drug treatments. Furthermore, to determine if any observed 
neurophysiological alterations were accompanied by behavioral changes, experiments 
measuring locomotor activity, sensitization and memory performance (novel object 
recognition) were performed. 
 
4.3.1 MEMRI procedure and data analysis 
 
The MEMRI method is based on the fact that the manganese ion Mn2+ functions as a Ca2+ 
analogue in vivo and is primarily taken up by activated neurons. Since Mn2+ is 
paramagnetic, it functions as an MRI contrast enhancing agent, and brain regions showing 
higher signal intensity are assumed to reflect regions of increased brain activity (Koretsky 
and Silva, 2004; Silva and Bock, 2008).  
 
One week prior to the scan, after the completion of all behavioral experiments, animals 
were surgically implanted with osmotic minipumps which delivered 200 μL of MnCl2 at a 
rate of 1 μL/h to a total dose of 120 mg/kg over the course of one week. One week after 
pump implantation and two weeks after the final drug treatment the MRI scan was 
performed in a 4.7 T scanner.  
 
MRI data processing was performed according to previously described methods (Friston 
et al., 1990; Jenkinson et al., 2002; Schwarz et al., 2006). For the region-of-interest 
analysis, 22 regions were selected on the basis of involvement in circuits mediating goal-
directed behavior as well as regions known to be affected by psychostimulant drugs 
(Sesack and Grace, 2010; Klomp et al., 2012; Noori et al., 2012). Region of interest 
analysis was also performed according to previously described methods (Maldjian et al., 
2003; Duff et al., 2007).  
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4.3.2 Behavioral experiments 
 
Locomotor activity and sensitization – locomotor activity was measured for up to 6 hours 
in novel cages after the first of two daily drug administrations during the first and last day 
of the drug treatments. Locomotor activity at both days was analyzed, and sensitization 
was assessed by comparing the locomotor activity on the first and last day of treatment.  
 
Recognition memory – memory function was assessed using the novel object recognition 
test (Motbey et al., 2012) in which the preference for exploring a novel object is used as a 
measure of recognition memory. The test was performed one week after the last drug 
treatment in a rectangular opaque blue box (50 x 80 x 30 cm). The test consisted of one 3-
min sample trial where the rat was exposed to two identical objects, followed by a 3-min 
test trial 15 min later where the rat was exposed to one novel object and one object 
which was previously used in the sample trial. The objects were a coffee mug (8 x 8 x 12 
cm, brown color) and two white translucent, rectangular plastic bottles taped together at 
the lids (3 x 3 x 18 cm). Objects were mounted securely to the bottom of the box using 
putty to prevent the rats from moving the objects.  Novel object preference was assessed 
by recording the test trials with a video camera and subsequent manual analysis by an 
operator blind to the experimental conditions using Ethograph v. 2.06 (St. Petersburg, 
Russia). Active exploration of objects such as touching and sniffing was counted as 
investigation. Merely being in the vicinity of or perching over the objects was not. 
 
4.3.3 Statistics 
 
Novel object recognition test performance and individual region of interest comparisons 
were analyzed using one-way or two-way analysis of variance followed by Fisher’s least 
significant difference post-hoc tests. Development of sensitization, or increased 
locomotor activity between the first and the last treatment day was analyzed by means of 
repeated-measures analysis of variance of average locomotor activity during the first two 
hours following drug administration on the first and last day.  
 
4.4 Study IV: In vitro toxicity and redox reactivity 
 
In order to identify possible mechanisms responsible for the differing effects of keto and 
non-keto amphetamines, we investigated the effects of these drugs on cytotoxicity and 
cellular proliferation in a neuroblastoma cell line in vitro and investigated differences in 
redox reactivity between these two classes of compounds. Finally, the effects of METH 
and 4-MMC on mitochondrial respiration were explored.  
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4.4.1 Cell culture 
 
SH-SY5Y neuroblastoma cells between passage 6 – 20 were maintained at 37 °C/5% CO2 in 
Dulbecco’s Modified Eagle Medium (DMEM/F12) containing 10% FBS and antimycin-A. 
This cell line was selected because it displays a catecholaminergic neuronal phenotype, as 
witnessed by the presence of markers such as TH, dopamine-β-hydroxylase and marked 
neurite outgrowth (Presgraves et al., 2004; Xie et al., 2010).  
 
4.4.2 Cytotoxicity assay 
 
Cytotoxicity was assessed by measuring the amount of lactate dehydrogenase released 
into the medium using the “Cytotoxicity Detection Kit” from Roche (Basel, Switzerland) 
according to the manufacturer’s instructions. In experiments employing the DAT-blocker 
GBR12909, the cells were pre-incubated for 1 h with GBR12909 prior to applying other 
drugs. The validity of the assay was confirmed using 5mM nicotinamide adenine 
dinucleotide or 2mM hydrogen peroxide as positive and negative controls. 
 
4.4.3 Cell proliferation and redox sensitivity assay 
 
The “Roche Cell Proliferation Reagent WST-1” containing WST-1 together with the 
intermediate electron acceptor 1-methoxy-5-methyl-phenazinium methyl sulfate was 
used for measuring cellular proliferation as well as redox sensitivity of keto and non-keto 
amphetamines. For the proliferation assays, the resulting formazan dye production after 
60 min incubation was measured spectrophotometrically at 440 nm. Similar to the 
cytotoxicity assay, the validity of the assay was confirmed using 5mM nicotinamide 
adenine dinucleotide or 2mM hydrogen peroxide as positive and negative controls.  
 
For the drug redox sensitivity assays, WST-1 was applied together with the various keto 
and non-keto amphetamines in PBS or DMEM/F12 medium without cells present. A 60 
min incubation time was also used for most of these experiments except the experiment 
measuring the reaction kinetics, were reactivity was measured every 10 min. 
 
4.4.4 Analysis of reaction products 
 
Detection and analysis of reaction products was performed using ultra-high performance 
liquid chromatography/high-resolution time-of-flight mass spectrometry under similar 
conditions as described previously (Sundström et al., 2013). 
  
64 
 
4.4.5 Mitochondrial respiration 
 
Cells were seeded at 10.000 cells per 80 μL well on XF cell culture microplates and grown 
normally. One hour prior the assay the normal culture medium was replaced with XF base 
medium containing glucose (10mM), L-glutamine (1mM) and pyruvic acid (10mM) and 
the microplate was placed in a CO2 free incubator until the time of the assay. Baseline and 
maximum mitochondrial respiration was measured using the XFe96 Analyzer (Seahorse 
Bioscience, MA, USA). Oxygen consumption rate was measured prior to, during, and after 
injections with the uncoupler carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone, 
and complex I+II inhibitors antimycin A + rotenone (final concentration 0.5μMand 
1µM+1μM, respectively). Basal respiration was calculated by subtracting non-
mitochondrial respiration (respiration following antimycin A + rotenone injection) from 
baseline respiration measured before any drugs were injected. Maximum respiration was 
calculated by subtracting non-mitochondrial respiration from the maximum respiration 
measured after injection of the uncoupler carbonyl cyanide 4-
(trifluoromethoxy)phenylhydrazone. 
 
4.4.6 Mitochondrial complex I/II assay 
 
The complex I/II assay was performed using the Oxygraph-2k (Oroboros Instruments 
GmbH, Innsbruck, Austria). For this assay, 8 mg of mice frontal cortex tissue was dissected 
and placed in shredder tubes containing MiRO6 respiration buffer (0.5mM ethylene glycol 
tetraacetic acid, 3mM MgCl2·6H20, 60mM K-lactobionate, 20mM taurine, 10mM KH2PO4, 
20mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 110mM sucrose, 1 g/l BSA, 
and 280 u/ml catalase) after which they were shredded using a SG3 shredder (Pressure 
Biosciences Inc., MA). The tube contents were diluted in 4.5 ml of MiRO6 and 
approximately 2.5 ml was transferred to the two Oxygraph-2k chambers for analysis.  
 
For the analysis, 4-MMC, METH (20mM final concentrations) or water were injected into 
the chambers and allowed to incubate for 20 min. After this, a substrate-uncoupler-
inhibitor titration protocol (Pesta and Gnaiger, 2012) was performed were substances 
were injected in the following order: L-malic acid (2mM), pyruvic acid (5mM), L-glutamic 
acid (10mM), adenosine diphosphate + Mg2+ (1mM), succinate (10mM), carbonyl cyanide 
4-(trifluoromethoxy)phenylhydrazone, rotenone (0.2μM), malonate (5µM) and antimycin 
A (2.5µM). Oxygen flux control ratio was determined for complex I+II (after succinate 
injection) and complex II only (after rotenone).  
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4.4.7 Statistics 
 
Lactate dehydrogenase release, WST-1 reduction and oxygen flux control ratios data were 
analyzed using analysis of variance and subsequent Dunnett’s or Fisher’s least significant 
difference post-hoc tests.   
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5. Results 
 
5.1 Study I: Effect of age on MDMA neurotoxicity 
  
5.1.1 Human SPECT neuroimaging 
 
SPECT imaging revealed no differences in midbrain [123I]ß-CIT binding between the early-
exposure group (1.30 ± 0.30) and the late-exposure group (1.24 ± 0.17). There were also 
no differences in frontal cortex [123I]ß-CIT binding between the early (0.77 ± 0.06) versus 
the late-exposure group (0.77 ± 0.08). Correlation and regression analysis indicated a 
strong inverse relationship between age of first ecstasy use and midbrain [123I]ß-CIT 
binding in the early, but not the late-exposure group. Specifically, the correlation 
between age of first exposure and SERT binding in the early-exposure group was r2 = 
0.789 and r = -0.888 (p < 0.01) while it was r2 = 0.032 and r = 0.179 (p > 0.05) in the late-
exposure group. In the frontal cortex, no relationship between age of first exposure and 
[123I]ß-CIT was found. Furthermore, other factors including age at the time of scanning, 
gender or duration and amount of ecstasy use also did not affect [123I]ß-CIT binding. 
5.1.2 Rat SERT binding 
 
In the control group, PFC [123I]ß-CIT binding was 21% higher in adult rats compared to 
adolescent rats (4.47 versus 3.55, p < 0.01). In other brain regions, including the midbrain, 
no differences in [123I]ß-CIT binding were found between rats at with MDMA during 
adolescence or adulthood. MDMA treatment reduced [123I]ß-CIT binding in all 
investigated brain regions except the striatum in both adolescent and adult rats (see 
Table 2 in I). Furthermore, an age-by-treatment interaction effect was observed in the 
PFC (p < 0.01) as adolescent rats appeared to show less reduction of [123I]ß-CIT binding in 
this brain region following MDMA treatment than the adult rats (a decrease of 35% and 
49%, respectively).  
 
5.2 Study II: Long-term effects of 4-MMC and MDMC 
 
5.2.1 Monoamine levels 
 
All significant effects of AMPH, 4-MMC or MDMC on levels of monoamine 
neurotransmitters and their metabolites two weeks after the final treatments are shown 
in Table 5.1 Exhaustive data from these experiments, including all measured transmitter 
and metabolite levels for rats and mice in all investigated brain regions can be found in II 
(Tables 2 and 3). 
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Drug Effects in rats Effects in mice 
AMPH 
 
 
 
DA: ↓ 45% in striatum 
 
5-HT: ↓ 33% in frontal cortex, ↓45% in striatum and ↓29% 
in hippocampus 
 
5-HIAA: ↓ 24% in striatum 
DA: ↓ 66% in striatum 
4-MMC No observed significant effects HVA: ↓ 22 in striatum 
MDMC 
 
 
5-HT: ↓ 43% in frontal cortex, ↓ 35% in striatum and ↓ 
38% in hippocampus 
 
5-HIAA: ↓ 21% in striatum and ↓ 22% in hippocampus 
No observed significant 
effects 
 
Table 5.1 Summary of the significant effect of AMPH, 4-MMC and MDMC treatments on levels of monoamine 
neurotransmitters and their metabolites two weeks after the final drug treatments in study II.  
 
 
 
Test Main results 
Elevated plus-maze No significant treatment effects 
T-maze 25% ↓ in alternation ratio following 4-MMC 
Locomotor activity No significant treatment effects 
Morris water maze Indications of increased reversal learning performance following 4-MMC 
and MDMC: 
 
4-MMC: 25% ↓ in time spent in old quadrant during the reversal learning 
probe trial. 
 
MDMC:  39% ↓ in time spent in the old quadrant and a 57% ↑ in the 
time spent in the new quadrant during the reversal learning probe trial. 
Tail suspension test No significant treatment effect 
 
Table 5.2 Summary of all results from behavioral tests performed 2 weeks or longer after the final treatment 
with 4-MMC or MDMC in study II. 
 
 
 
Test Main result 
Locomotor activity/sensitization ↑ Acute locomotor activity following METH and 4-MMC on both the 
first and last day of drug treatments. 
 
35% ↑ in total locomotor activity following METH on the last day of 
drug treatments. 
 
No evidence of locomotor sensitization at the last day of drug 
treatments. 
Novel object recognition No significant treatment effects. 
 
Table 5.3 Summary of the results obtained from the behavioral experiments in study III.  
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5.2.2 SERT and DAT binding 
 
MDMC produced a 24% decrease in PFC [3H]paroxetine binding (p < 0.05) and a 65% 
decrease in hippocampal [3H]paroxetine binding, but had no effect on [3H]mazindol 
binding in the striatum. On the other hand, 4-MMC had no effect on [3H]paroxetine or 
[3H]mazindol in any of the investigated brain regions.  
 
5.2.3 Behavioral experiments 
 
A summary of the results obtained from the behavioral experiments are shown in Table 
5.2. For complete results, please refer to II (Table 2 and results section). 
 
As seen in Table 5.2, the results indicate that only behavior related to memory, but not to 
anxiety or depression, was affected by 4-MMC and MDMC. However, the observed 
effects of 4-MMC and MDMC on memory are ambiguous. Although 4-MMC appears to 
decrease working memory performance, it actually appears to improve the performance 
on aspects of spatial memory. Specifically, both MDMC and 4-MMC appeared to improve 
spatial reversal learning.  
 
5.3 Study III: Effect of METH and 4-MMC on brain activity 
 
5.3.1 Assessment of brain activity with MEMRI 
 
Functional brain activity – METH and 4-MMC produced surprisingly different long-term 
effects on brain activity. METH produced a widespread reduction in brain activity in 
regions including the primary motor cortex, cingulate, insular cortex, striatum, thalamus, 
hippocampus, amygdala, superior colliculus and raphe nucleus. On the other hand, 4-
MMC produced an increase in brain activity. The increases in activity were much less 
widespread and were limited primarily to certain cortical regions and the hypothalamus. 
Detailed maps of altered brain activity following METH and 4-MMC as are shown in III 
(Fig. 4 and 5)  
 
Region of interest analysis – Out of the 22 regions of interest that were investigated, 
METH treatment produced significant decreases in brain activity in the nucleus 
accumbens core, caudate/putamen, lateral globus pallidus, cingulate cortex, raphe 
nucleus and superior colliculus. In all regions, the decreases were between 6% and 7% (all 
p < 0.05). Conversely, 4-MMC produced a 10% increase in brain activity. This effect was 
limited to only one region of interest, namely the hypothalamus (p < 0.01).  
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5.3.2 Behavioral experiments 
 
The significant results obtained from the locomotor activity and sensitization experiment 
as well as the novel object recognition experiment is shown in Table 5.3. The data is also 
summarized graphically in Fig. 2 (locomotor activity) and Fig. 3 (novel object recognition) 
of III. 
 
The most important result from the behavioral experiment was that no effect was 
observed on memory performance. This was contrary to expectation, as a decrease in 
memory performance had previously been reported using the same test and 4-MMC 
doses, although with a 25% higher cumulative 4-MMC dose (Motbey et al., 2012). 
 
In this experiment we also did not find any evidence of locomotor sensitization. This was 
not unexpected, as sensitization develops preferentially following treatments with low 
doses of psychostimulants, and not high doses, such as employed here (Frey et al., 1997). 
Furthermore, a previous study employing the same 4-MMC doses as here also reported 
that no sensitization had taken place (Motbey et al., 2012). The development of 
locomotor sensitization is associated with drug addiction (Robinson and Berridge, 1993), 
and the fact that no sensitization was observed in this experiment strengthens the 
hypothesis that the observed changes in brain activity are due to neurophysiological 
processes unrelated to addiction. 
 
5.4 Study IV: In vitro toxicity and redox reactivity 
 
5.4.1 Cytotoxicity and cellular proliferation 
 
Cytotoxicity – The cytotoxic effects of a 48 h treatment with 4-MMC became apparent at 
concentrations of 500µM and higher. At this concentration a 16% increase in lactate 
dehydrogenase release was observed (p < 0.001) compared to untreated cells. The 
observed lactate dehydrogenase release increased to 75% (p < 0.001) at 2mM, the 
highest concentration tested. MDMC and METH produced significant increases in lactate 
dehydrogenase release of 24% (p < 0.001) and 5% (p < 0.05), respectively. However, this 
effect was only observed at the highest concentration tested (2mM). Notably, all drugs 
produced a decrease in lactate dehydrogenase release of between 18% and 34% (all p < 
0.001) at concentrations between 2 – 100µM. Furthermore, pre-treatment with the DAT 
blocker GBR12909 reduced 2mM 4-MMC-induced lactate dehydrogenase release by 38% 
(p < 0.01).  
 
Cellular proliferation – As expected, METH produced a decrease in cell viability. At 1mM, a 
19% decrease in viability was observed (p < 0.01). At the 2mM concentration the 
decrease had reached 20% (p < 0.001). Notably, both 4-MMC and MDMC did not produce 
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a decrease in WST-1 reduction indicative of decreased cellular proliferation. Instead they 
produced an exceptionally large and dose-dependent increase in WST-1 reduction of up 
to 280% for 4-MMC and 187% for MDMC (both p <0.001). Examination of the cells under 
a light microscope, however, did not reveal any apparent increase in cellular proliferation 
in the drug-treated cells (IV, Fig. 2). 
 
5.4.2 Redox reactivity of β-keto amphetamines 
 
The experiments using WST-1 as a redox sensitivity assay produced the following main 
results: 
 
1. The observed increase in WST-1 reduction occurred with all keto amphetamines 4-
MMC, MDMC, methcathinone, 3,4-dimethylmethcathinone, 4-
bromomethcathinone/brephedrone, α-methylamine-byturophenone/buphedrone and 
bupropion, but not with any of the non-keto amphetamines AMPH, METH, MDMA, 3-
fluoroamphetamine (3-FA) and 4-fluoroamphetamine (4-FA). 
2. The kinetics of the observed reaction between 4-MMC and WST-1 was linear between 
0 and 60 min. 
3.  Although the reaction occurred in phosphate buffered saline, the presence of 
DMEM/F12 culture medium increased the reactivity. 
4. The reactivity was increased as a function of increasing pH (range 6.4 – 8.4). 
5. The reactivity was blocked or attenuated by the antioxidants and superoxide 
scavengers including L-Ascorbic acid-2-phosphate, 4-Hydroxy-TEMPO and Tiron. 
 
The results are also summarized graphically in IV, Fig. 4 and 5. 
5.4.3 Effects on mitochondria 
 
Respiration – Figure 3.1 shows the effect of METH or 4-MMC either alone or in 
combination with GBR12909 on basal and maximum respiration. Both METH and 4-MMC 
produced dose-dependent decreases in baseline and maximum respiration. The decrease 
in respiration following 4-MMC was significantly larger than the decrease observed after 
METH. Furthermore, GBR12909 blocked the 4-MMC-induced decreases in respiration. 
 
Complex I/II assay – Following a 20 min incubation with METH, a 69% decrease in 
complex II-mediated flux control ratio was observed (p < 0.01). No such effect was found 
following incubation with 4-MMC.  
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Figure 5.1 The effects of METH or 4-MMC alone or in combination with DAT-blocker GBR12909 on basal 
respiration (left) maximum respiration (right). The basal and maximum metrics were calculated by subtracting 
oxygen consumption after rotenone + antimycin A injection from the baseline pre-drug respiration or the 
maximum carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone-induced respiration. Data presented as 
mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. N ≥ 5 per group. 
 
 
5.4.4 Reaction products 
 
Analysis of the reaction products following the reaction of 4-MMC or MDMC with WST-1 
yielded the two sets of compounds shown in Fig. 5.1 (see IV, Fig. 6 for the corresponding 
chromatograms). Reaction of WST-1 with 4-MMC resulted in the production of N,4-
dimethylbenzamide and N-Ac-4-MMC. The reaction with MDMC produced 3,4-
methylenedioxy-N-methylbenzamide and N-Acetyl-MDMC. Additionally, reduced WST-1 
was detected in both samples. 
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Figure 5.1 Incubation of 4-MMC and MDMC with the electron acceptor WST-1 produced N,4-
dimethylbenzamine and 3,4-methylenedioxy-N-methylbenzamine, respectively.  
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6. Discussion 
 
The first three studies demonstrate that the non-keto amphetamines AMPH, METH and 
MDMA produce long-term reductions in brain levels of monoamines, monoamine 
transporter binding or brain activity. However, alterations in these physiological 
parameters are not associated with any consistent effect on cognitive function or other 
neurobehavioral measurements. Conversely, the keto-amphetamine 4-MMC does not 
produce any long-term alterations in brain levels of monoamines, transporter binding or 
widespread decreases in brain activity that would be suggestive of neurotoxicity or 
detrimental long-term neuropharmacological or neurophysiological adaptations. MDMC 
produces long-term effects on the 5-HT system that are similar to MDMA. Neither keto 
amphetamines produce any consistent effect on cognition, mood or anxiety. Finally, in 
the last study it is shown that keto and non-keto amphetamines possess different redox 
properties and have different effects at the level of the mitochondrial ETC, something 
which may play a role in their differing biological and toxicological effects. 
 
What follows is a brief discussions of specific results obtained in the individual studies, 
followed by a more general discussion on cathinone toxicity, the limitations associated 
with the models used in the present studies, as well as future directions for the study of 
substituted amphetamines and other novel psychoactive substances in general. 
 
6.1 Effect of age on MDMA neurotoxicity 
 
6.1.1 No clear age-of-first exposure effect observed in humans 
 
The hypothesis that the neurotoxic effects of MDMA are dependent upon the initial 
integrity 5-HT system is not supported by the obtained data. In humans, midbrain SERT 
density decreases with increasing age in individuals 18 and older, whereas no age-
associated changes in SERT binding are observed prior to the age of 18 (Dahlstrom et al. 
2000, van Dyck et al. 2000). For this reason, it was expected that, due to the natural age-
related loss of SERT, decreases in midbrain SERT density would be less pronounced in 
individuals exposed to MDMA at a later age in the late-exposure group. However, no 
correlation between age of first exposure and SERT density was found in adult subjects. 
Furthermore, in the early-exposure group, where no age-related changes were 
hypothesized to take place, a negative correlation between age of first MDMA exposure 
and midbrain SERT density was observed.  
 
One explanation for the observed effect in the early-exposure group is that 5-HT exerts 
neurotrophic effects during development (Lauder and Krebs 1978, Lauder et al. 1983), 
which suggests that increases in 5-HT levels due to MDMA may produce neurotrophic 
effects. It has previously been shown that MDMA exerts neurotrophic effects on midbrain 
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primary cultures in vitro (Azmitia et al., 1990). However, it is difficult to predict whether a 
similar effect would occur in vivo. There are important differences between short-term 
application of MDMA in an in vitro model and human MDMA use. Importantly, MDMA 
produces a quick peak, followed by a more long-term decrease in 5-HT levels (McCann et 
al., 1994). Therefore, it is perhaps unlikely that, on average, 5-HT levels would be much 
higher as a result of MDMA in human recreational users.  
 
A number of limitations apply to this experiment. The sample size of the early-exposure 
group was relatively small. Furthermore, the age of first exposure to MDMA, as well as 
the total consumption of MDMA and other drugs were based solely on self-reports and 
may thus not be entirely accurate. Finally, it is possible that the results are primarily due 
to pre-existing differences between individuals exposed to MDMA at different ages. With 
these limitations in mind, it is difficult to draw definitive conclusions based on this 
neuroimaging data. 
 
6.1.2 Age-related increase in SERT density increases MDMA neurotoxicity in 
rats 
 
Unlike what was seen in the human study, the results from the rat experiment do support 
the hypothesis that increased SERT density conveys vulnerability to the neurotoxic effects 
of MDMA. In rats, SERT densities in the midbrain reach a plateau during weaning, 
whereas in later maturing brain regions, such as the PFC, there is a steady increase in 
SERT density from weaning till old age (Brunello et al. 1985, Moll et al. 2000, Slotkin et al. 
1997). Accordingly, the results indicated higher baseline PFC SERT and increased MDMA-
induced PFC SERT loss in adult compared to adolescent rats. Furthermore, no age-related 
differences in SERT loss were observed in the midbrain or any other brain regions where 
no differences in baseline SERT levels were observed. Thus, the results from this 
experiment suggest that, compared to adult rats, MDMA is less toxic to the 5-HT system 
in the PFC of adolescent rats. 
 
Unfortunately it is difficult to compare the results obtained from the rat brain SERT 
binding with the human SPECT neuroimaging due to ontogenetic differences in SERT 
expression across species, but it is clear that there is no neurotrophic effect of MDMA in 
rats, like human data may have suggested. This may have been because the employed 
dose of 10 mg/kg administered in a binge-like fashion, is very high (Baumann et al., 2007), 
and may have reached a level were the toxic effects of MDMA outweigh its neurotrophic 
effects. Another general limitation is related to the fact that the [123I]β-CIT shows affinity 
for both DAT and SERT, with DAT and SERT binding occurring preferentially at different 
times after administration. Due to the presence of DAT in the midbrain, thalamus and 
cortex, the observed changes cannot with certainty be attributed to altered SERT 
availability. Nonetheless, displacement studies suggest that binding in these regions is 
primarily associated with SERT (Scheffel et al., 1992; Farde et al., 1994). Furthermore, the 
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analysis time was selected based on the time period of maximum SERT binding, 
suggesting that the observed changes in brain regions besides the striatum primarily 
reflect SERT-specific binding. 
 
6.2 Neurotoxicity of 4-MMC and MDMC 
 
As expected, AMPH produced a strong reduction in DA levels in both mice and rats. 
Surprisingly, however, 4-MMC did not produce, aside from a minor reduction of striatal 
HVA levels in mice, any significant effects in mice or rats. MDMC, conversely, produced a 
decrease in 5-HT levels in all brain regions investigated. A similar picture emerged with 
regards to monoamine transporters, as MDMC reduced SERT binding, while no effects on 
SERT or DAT transporters were observed after 4-MMC. Memory function was also 
affected, and this is discussed in section 6.3.2. 
 
6.2.1. 4-MMC does not affect monoamine and transporter levels 
 
The most important and unexpected result was that 4-MMC did not produce any long-
term decreases in the levels of DA, 5-HT or their respective transporters. If one uses these 
measurements as evidence of neurotoxicity, it would suggest that no neurotoxicity took 
place following 4-MMC treatments. This is interesting, considering the similarity of this 
drug, in terms of both structure and pharmacology, to METH. Similar experiments have 
recently been done by several other groups, and it has now repeatedly been shown that 
similar binge-treatments with 4-MMC produce no effect on levels of DA, 5-HT, TH, 
microglial activation or glial fibrillary acidic protein between 2 days and several weeks 
after treatment (Angoa-Perez et al., 2012; Baumann et al., 2012; Motbey et al., 2012). 
The apparent lack of neurotoxic effects of 4-MMC is striking and provides information 
that is important for both public health policy and harm reduction strategies related to 
this substance. 
 
6.2.2 MDMC reduces 5-HT and SERT levels 
 
The effects of MDMC have been less studied, thus making it harder to draw definitive 
conclusions regarding the long-term effects of this drug. One study reported no long-term 
effects on DA or 5-HT levels at doses up to 3 times 10 mg/kg (Baumann et al., 2012). This 
suggests that MDMC can produce a long-term reduction in 5-HT at very high, but not at 
lower doses. It also shows that MDMC is similar to MDMA, in that they both affect the 5-
HT system, although higher doses of MDMC than MDMA are required to produce this 
effect. Nonetheless, relative effects on 5-HT levels at equimolar doses may not be entirely 
representative of real-life differences in toxicity, due to differences in the potency of the 
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subjective effects and commonly consumed recreational doses between the two 
substances. 
 
Another interesting similarity between MDMC and MDMA is related to the observed 
species differences in their effects. In this study, the long-term effect of MDMC on 5-HT 
levels was observed only in rats, but not in mice. This is reminiscent of the species 
difference of MDMA between mice and rats, where MDMA reduces 5-HT levels in rats, 
while reducing DA levels in mice (Logan et al., 1988). With MDMA it has been suggested 
that this is because of metabolic differences between mice and rats, with hepatic 
metabolites toxic to 5-HT neurons being more important in rats, while DA release and 
subsequent ROS toxicity to DA neurons being the primary mechanism in mice (Stone et 
al., 1987; de la Torre and Farre, 2004). 
 
6.3 Effect of METH and 4-MMC on brain activity and memory 
 
6.3.1 Contrasting effects of 4-MMC and METH on brain activity 
 
The brain regions showing decreased activity after METH, such as the striatum, 
correspond closely to regions known to be vulnerable to METH-induced neurotoxicity 
(Seiden et al., 1988; Cass and Manning, 1999; Haughey et al., 2000; Schroder et al., 2003). 
They also overlap closely with regions showing altered metabolism in abstinent human 
METH users (Volkow et al., 2001b; London et al., 2004; Wang et al., 2004). This speaks for 
the construct validity of the method in terms of detecting psychostimulant-induced 
alterations in brain function and, furthermore, suggests MEMRI may be an interesting 
translational method that may help bridge the gap between human neuroimaging and 
preclinical studies on amphetamine neurotoxicity. 
 
The differences between METH and 4-MMC in terms of brain activity are striking. The 
MEMRI method has previously been employed to detect changes in brain activity 
following various behavioral paradigms (Bangasser et al., 2013; Hoch et al., 2013). The 
fact that this method is sensitive enough to detect neurophysiological alterations 
following only behavioral paradigms, suggests it may also detect long-term alterations 
following 4-MMC that are not detectable using neurochemical and immunological 
methods. Although regions of altered activity were observed, they were much more 
limited than what was observed with METH. Furthermore, unlike METH, 4-MMC 
produced only increased brain activity. This would appear to confirm the results from 
previous experiments, namely that the long-term effects of 4-MMC are very limited when 
compared to METH. 
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6.3.2 Behavioral tests of cognition provide ambiguous results 
 
No effect was found of 4-MMC or MDMC on tests aside from some of the tests of 
memory function. The only long-term after-effect of MDMC was an improvement in 
spatial reversal learning. Improvement in reversal learning was also observed after 4-
MMC, but this drug in turn reduced working memory performance in the T-maze while 
having no effect on object recognition (studies II and III). The observed effect on working 
memory is interesting as decreased working memory performance has also been 
reported in human 4-MMC users, although this effect was measured while users were 
acutely under the influence of the drug (Freeman et al., 2012). On the other hand, a study 
in rhesus macaques, also performed while animals were under the influence of 4-MMC, 
found no evidence of detrimental effects on working memory, and actually reported a 
pronounced improvement in visuospatial learning and memory (Wright et al., 2012a). 
However, assessments made during acute intoxication are not a good reference when 
one is interested in the long-term residual effects. 
 
Thus, the implications of the results obtained from the behavioral tests in these studies 
depend largely on how they are interpreted. Based on the decrease in working memory 
performance one could argue that 4-MMC has a detrimental effect on memory, but this 
would not do justice to the fact that other tests produced no measurable effect or in fact 
produced an improvement in certain test metrics. One thing that can be said is that the 
behavioral results are very much in accord with previous literature on the long-term 
effects of amphetamines on cognition, which is equally ambiguous and inconsistent (see 
2.6.1.3). They highlight that behavioral paradigms, as they are presently used, are not a 
very good method for investigating the long-term effects of amphetamines on cognition 
as interfering factors, such as stress from high-dose drug treatments, could easily affect 
the results. 
 
6.3.2.1 A role for stress? 
 
The inconsistency of the results obtained from behavioral tests measuring memory 
performance raises the question if they really measure any drug toxicity-related 
alterations in these parameters. It is likely that performance is affected also by other 
parameters likely to be affected by drug treatments, such as stress. For instance, it is 
likely that non-contingent, high-dose amphetamine administration induces a much higher 
level of stress than corresponding saline injections in experimental animals. 
 
It is therefore notable that one of the few brain regions affected by 4-MMC on the 
MEMRI scan was the hypothalamus, which showed a robust 10% increase in activity 
compared to saline-treated animals. Moreover, when looking at novel object recognition 
performance in the same experiment, the percentage of time spent exploring the novel 
object was significantly correlated to signal intensity in two brain regions across all 
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subjects (unpublished data). The first region was the ventral hippocampus (r = 0.43, N = 
22, p < 0.05), which was expected, considering the importance of the hippocampus in 
learning and memory (Felix and Levin, 1997; Lipska et al., 2002; Broadbent et al., 2004; 
Winters et al., 2004). The second region showing significant correlation was the lateral 
hypothalamus (r = 0.48, N = 22, p < 0.05), a region known for its pivotal role in mediating 
the stress response (Herman and Cullinan, 1997; Ida et al., 2000). This could indicate that 
stress may be an important factor in determining the performance in rodent tests of 
memory after amphetamines. The effect of stress on memory performance is complex, 
and both improvement and impairment of memory function as a result of stress has been 
reported (Park et al., 2001; Duncko et al., 2009; Sunada et al., 2010), which could explain 
the largely inconsistent results obtained from animal models of cognition following 
treatment with 4-MMC, but also with other amphetamines.  
 
Further work is needed to establish the exact role of stress in mediating the performance 
of rodents in behavioral tests of memory function following exposure 4-MMC and 
amphetamines in general. Meanwhile, conclusions based on these results should be 
drawn with great caution.   
 
6.4 Keto amphetamine redox reactivity and toxicity 
 
6.4.1 β-keto amphetamines produce cytotoxicity in vitro 
 
Previously it has been shown that METH is toxic and causes cell death in SH-SY5Y cells at 
concentrations in a similar range as those used here (Wu et al., 2007; Wisessmith et al., 
2009; Nara et al., 2010; Suwanjang et al., 2010). Here, we show that 4-MMC and MDMC 
produce a higher degree of cytotoxicity than METH. Furthermore, 4-MMC toxicity was 
partially blocked by DAT inhibitor GBR12909.  
 
A recent study reported on the in vitro toxicity of a range of β-keto amphetamines in rat 
hepatocytes (Araujo et al., 2014). Additionally, there is one report of MDMC toxicity in 
Chinese hamster ovary cells transfected with SERT DAT and NET. Here, only the SERT 
transfected cells displayed increased cytotoxicity after MDMC incubation at 100 μM. 
However, DAT SERT and NET transfection all increased the toxicity of METH when the two 
drugs were administered together (Sogawa et al., 2011). This is reminiscent of the in vivo 
findings of 4-MMC not being toxic on its own, but increasing the toxicity of METH when 
administered together (Angoa-Perez et al., 2013). Aside from the studies mentioned 
above, this appears to be the first report specifically on the in vitro toxicology of 
substituted cathinones in neuron-like cells.  
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6.4.2 β-keto amphetamines possess specific redox reactivity 
 
The increase in WST-1 reduction observed in the experiments set out to measure cellular 
proliferation after 4-MMC and MDMC treatment was striking due to the magnitude of the 
reactivity, and the fact that no evidence of increased proliferation was visible when 
examining the cells visually. It suggested that another factor was responsible for the 
increased reactivity. WST-1 is a water soluble tetrazolium salt, and the WST-1 assay is a 
colorimetric assay based upon the reduction of the pale yellow WST-1, via an 
intermediate electron acceptor, to the darker colored formazan (Berridge et al., 2005). 
The next step was therefore to investigate the possibility that β-keto amphetamines can 
function as reducing agents in the presence of this electron acceptor. 
 
6.4.3 β-keto amphetamine as reducing agents: biological significance 
 
The experiments using the WST-1 reagents as a redox sensitivity assay clearly indicate 
that β-keto amphetamines are powerful and selective reducing agents in the presence of 
an electron acceptor, compared to their non-keto counterparts. Furthermore, the 
reducing properties appear to be enhanced as a function of increasing pH in the 
physiological range and are blocked by antioxidants. This raises the question whether or 
not this property has any biological or toxicological significance. One possibility is that the 
reducing properties of β-keto amphetamines could interfere with cellular redox buffering 
systems. Such is the case, for instance, with redox-active iron, which has been shown to 
be a source of oxidative stress associated with apoptosis (Smith et al., 1997; Savory et al., 
1999).  
 
To study the possible biological significance of the redox properties of 4-MMC it was 
chosen to study the effects on mitochondria, as this organelle is dependent upon a high 
volume of redox reactions for normal functioning and also has a slightly alkaline pH. The 
results showed that METH, but not 4-MMC, produced an inhibition of mitochondrial 
complex II. The observed effect of METH on complex II is consistent with previous findings 
demonstrating inhibition of this complex by METH (see section 2.7.2). The finding that 4-
MMC produced no apparent inhibition of specific mitochondrial complexes is surprising, 
considering the fact that it produced a general decrease in both baseline and maximum 
mitochondrial respiration that was much higher than what was observed after METH.  
 
One reason for the observed discrepancy may be that different types of assays were used 
for the respiration assay and complex I/II assay. Whereas respiration was measured after 
one day incubation, the complex I/II assay was performed after only 20 min incubation 
with the drugs, albeit in a higher concentration. Thus, it is possible that more time may 
have been needed to induce inhibition of mitochondrial complexes, or that the longer 
incubation led to production of metabolites with more potent ETC-inhibitory effects. 
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Furthermore, the complex I/II assay was performed on mouse cortical tissue 
homogenates, whereas the respiration experiments were performed in SH-SY5Y cells.  
 
The redox properties of β-keto amphetamines may play an important role in their 
interaction with cellular targets. Further study of the exact biological significance of β-
keto amphetamine redox properties in terms of their interaction with mitochondria and 
other cellular targets is clearly warranted.  
 
6.4.4 The cathinones 4-MMC and MDMC produce breakdown products 
 
The analysis of 4-MMC and MDMC reaction products was initially performed in order to 
test the hypothesis that these drugs were capable of forming adducts with amino acids, 
something which has been implicated in the neurotoxicity of ketone-containing 
substances such as acrylamide (Lopachin and Decaprio, 2005). We did not find any 
evidence of adduct formation, but instead observed the breakdown products shown in 
Fig. 5.1. 
 
In the 4-MMC sample N,4-dimethylbenzamide and N-Acetyl-4-MMC was detected. 
Accordingly, the MDMC sample contained the dioxol-ring substituted analogues of these 
compounds, namely 3,4-methylenedioxy-N-methylbenzamide and N-Acetyl-MDMC. 
Interestingly, these products were previously detected after incubation of 4-MMC in 
alkaline pH (Tsujikawa et al., 2012), and suggest a specific degradation pathway whereby 
4-MMC is converted via two intermediate substances to N,4-dimethylbenzamide, in the 
process releasing acetic acid, which reacts with remaining 4-MMC to produce N-Acetyl-4-
MMC (see IV, Fig. 9). Here, we demonstrate that this reaction occurs also in the presence 
of an electron acceptor.  
 
Currently, the biological significance of these breakdown products is unknown. A further 
investigation into breakdown products of keto amphetamines is needed in order to draw 
conclusions about their toxicological relevance. 
 
6.5 Neurotoxicity of cathinones and amphetamines 
 
6.5.1 Cathinones are less neurotoxic than amphetamines 
 
It is interesting to note that the occurrence of novel psychoactive substances that started 
gaining pace in 2009 is not the first time there has been interest in the toxicology of 
cathinones. A handful of studies investigated the neurotoxicity of cathinone and 
methcathinone in the 1980s and 90s, as it enjoyed brief popularity as a recreational drug 
and due to khat use (Wagner et al., 1982; Roper, 1986; Gygi et al., 1996; Sparago et al., 
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1996). Sparago et al. (1996) treated animals with methcathinone and reported reductions 
in DA levels after a two week survival interval, but only at doses of 80 mg/kg or higher 
administered repeatedly. Gygi et al. (1996) reported no effects at doses of 10-20 mg/kg 
but found that doses of 30 mg/kg were associated with decreases in DA, TH, 5-HT and 
TPH levels. However, the 30 mg/kg dose also produced high lethality and, furthermore, all 
measurements were performed no later than 3 days after the final drug treatments, and 
thus did not strictly measure long-term effects.  
 
The previous interest in cathinones, however, was brief. Interest soon shifted towards 
the, at that time, more prevalent MDMA and METH. But the enormous increase in novel 
psychoactive substance use in recent years has led to renewed research interest in 
cathinones. The data presented in this thesis have been published simultaneously with a 
number of other studies initiated in response to the recent increase in substituted 
cathinone use (see section 5.2.3). Taking into consideration the previous and current data 
on cathinone neurotoxicity, together with the results presented in this thesis, it appears 
that cathinones have a more favourable safety profile than amphetamines. From a harm-
reduction point of view this is important information. However, it should be stressed that 
the present data focuses on neurotoxicity. Amphetamines can, particularly at high doses, 
exert powerful and potentially detrimental effects on the hepatic, renal and 
cardiovascular systems (Carvalho et al., 2012), and it is still unclear how cathinones 
compare to amphetamines in this respect. 
 
6.5.2 Added stress factors may induce 4-MMC neurotoxicity 
 
The results presented above suggest that 4-MMC produces little, if any, toxicity when 
administered on its own under normal conditions. However, a few circumstances have 
been identified under which 4-MMC does appear to produce or enhance neurotoxicity in 
a fashion reminiscent of what is seen with non-keto amphetamines. 
 
One such condition is administration of 4-MMC at high (> 27°C) ambient temperatures. 
For instance, decreased 5-HT uptake has been demonstrated in synaptosomes prepared 
from rats treated with 4-MMC at high ambient temperatures one week earlier (Hadlock 
et al. 2011). Similarly, it was reported that binge 4-MMC treatments produced a 
reduction in DAT and SERT binding in mice when measured 3 days after the final drug 
treatment. However most of these values restored to control levels when measured at 
the 7 day time point. Furthermore, there were no clear effects in terms of TH, TPH and 
glial fibrillary acidic protein activity levels at 7 days either (Martinez-Clemente et al., 
2014). 
 
In a set of interesting experiments, one group investigated the interaction between 4-
MMC and non-keto amphetamine neurotoxicity in mice. Specifically, they investigated if 
concurrent treatment with 4-MMC would affect the depletion of striatal and hippocampal 
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DA and 5-HT caused by METH and MDMA. The results confirmed that 4-MMC on its own 
did not affect monoamine levels, but showed that 4-MMC did exacerbate METH- and 
MDMA-induced depletions of striatal DA when the two drugs were administered 
together. On the other hand, 4-MMC did not appear to exacerbate the effects of these 
drugs on hippocampal 5-HT levels (Angoa-Perez et al., 2013; Angoa-Perez et al., 2014). 
 
The experiments on the effect of ambient temperatures and co-treatment with non-keto 
amphetamines described above are particularly valuable as they provide specific and 
useful harm reduction information. 
 
6.6. Limitations 
 
The results presented in this thesis provide important new information about the 
potential neurotoxicity and long-term neuropharmacological effects of new 
amphetamine-type stimulants obtained using a wide range of methods, ranging from 
studies in human recreational users to preclinical and in vitro experiments. All these 
methods are subject to certain limitations, which are addressed in this section. 
 
 6.6.1 Human studies 
 
The results from the human neuroimaging study presented in this thesis (I) did not 
support the hypothesis or the data obtained from the analogous animal experiment. 
Unfortunately, the inconsistency of data appears to be a general trend in studies of 
human amphetamine users. For instance, although DAT binding was decreased in 
abstinent METH users (McCann et al., 2008), there was no correlation between DAT 
binding and the time of abstinence or between DAT binding and measures of cognitive 
function (Johanson et al., 2006). With regards to MDMA, one study (McCann et al., 
1998a) reported decreased SERT binding in MDMA users but no correlation between 
decreases in SERT binding and time of abstinence. Investigations of cerebral metabolism 
and blood flow also demonstrate alterations in amphetamine users compared to control 
groups that do not show any correlation between cognitive test performance (Daumann 
et al., 2003; Daumann et al., 2005; Becker et al., 2013).  
 
With regards to effects on cognition, the results are not clear either. Although groups of 
abstinent amphetamine users sometimes display statistically significant lower scores on 
memory tests compared to control groups (see section 2.6), they still perform well within 
the normal range, making it unclear if it really can be considered a deficiency, due to the 
lack of any clinically significant impairment (Hart et al., 2012). The issue is particularly 
salient as the cross-sectional design of most studies makes it impossible to draw 
conclusions with regards to causality. Thus, the question remains whether the observed 
effects are actually due to drug consumption or if amphetamine users exhibit pre-existing 
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differences in parameters such as monoamine transporter binding and memory function, 
compared to non-users. 
 
This question was one important reason for performing the MEMRI study presented in 
this thesis. This study demonstrated changes in brain activity following METH that 
showed a large degree of overlap with those shown to be affected in abstinent METH 
users (see III and section 5.3.2). Translating the results of this study would suggest that 
changes in brain chemistry could indeed be related to amphetamine use.  Further MEMRI 
studies are clearly warranted to gain more insight into the dose-dependency and time 
course of the observed effects. However, no effect was found on memory function, 
meaning any observed effect on memory in human studies may just reflect pre-existing 
differences. The exact functional ramification, if any, of amphetamine-induced long-term 
alterations in neurophysiological parameters remain to be determined 
 
6.6.2 Preclinical studies 
 
The animal studies presented in this thesis (I, II, III) have all employed relatively high drug 
doses between 5 and 30 mg/kg administered in a binge-like fashion over several days. 
One of the major controversies in the preclinical literature on amphetamine toxicity is the 
issue of interspecies scaling (McCann and Ricaurte, 2001; Vollenweider et al., 2001). 
Rodents are typically administered doses of 10-20 mg/kg or more, often repeatedly over 
the course of one to several days, whereas a human recreational dose of MDMA is 
around 1.3 mg/kg (based on a 100 mg pill consumed by an 80 kg individual). Even with 
several tablets consumed in one night, the cumulative dose usually does not come close 
to the doses regularly administered to rodents in a laboratory setting. The rationale for 
these high doses comes from the concept of allometric interspecies scaling, a technique 
commonly used in medicine development to calculate human doses based on animal 
data. This method is based on compensating for faster basal metabolic rate, heart rate 
and circulation times that are expected to result in more rapid drug metabolism in smaller 
animals. However, there are a number of objections against using this formula for certain 
substances, particularly amphetamines, which are extensively metabolized, thereby 
complicating simple scaling based on basal metabolic rate. MDMA also displays nonlinear 
kinetics, with increasing doses producing unexpectedly high plasma concentrations, and, 
furthermore, possible species-dependent differences in metabolism, tissue uptake or 
other parameters are also not taken into consideration (Baumann et al., 2007). 
 
Due to the problems associated with allometric scaling, Baumann et al. (2007) has 
suggested using an alternative method, effects scaling, to compensate for differences 
between species. This method is based on establishing the lowest dose which produces a 
specific pharmacological effect, such as measurable neurotransmitter or hormone 
release, or the dose needed to produce specific behavioral effects such as reinforcement 
and drug discrimination. This method appears more sensible in this context as it is based 
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purely on the effects of the drug at a certain dose, without having to predetermine 
numerous factors as would be required in order to correctly employ allometric scaling. 
When using effects scaling, the doses required to achieve similar amounts of 5-HT 
release, prolactin secretion, reinforcement or drug discrimination in rodents and humans 
are very similar, and all in the 1-3 mg/kg range (Baumann et al., 2007), closely 
corresponding to the doses used recreationally by humans. More importantly, when 
administered at these doses (< 5 mg/kg) there is no evidence of long-lasting monoamine 
depletions (O'Shea et al., 1998; Baumann et al., 2007). 
 
Another important issue which limits the validity of preclinical studies is related to the 
dosing regimens commonly employed. Most commonly, the drug is administered as 
multiple, equal injections of the compounds. Aside from the issues associated with 
allometric scaling, on which these high doses are based, they are a poor reflection of how 
humans commonly use psychostimulants, as human use is generally characterized by 
initial light use, which gradually escalates to the intake of larger amounts. This is 
particularly relevant as several studies show that preconditioning animals with low doses 
of METH or MDMA is protective, and drastically reduces the effect of subsequent high 
drug doses on monoamine levels and ROS production (Graham et al., 2008; Cadet et al., 
2009; El Ayadi and Zigmond, 2011; Hodges et al., 2011; Mayado et al., 2011). Other 
factors, such as voluntary exercise (Toborek et al., 2013) also offer protection against 
METH toxicity and indicate that administration of high-doses of amphetamines in 
relatively low-enriched caging environment may not correctly model the effects in 
humans. 
 
Importantly, effects scaling or naturalistic dosing regimens were not employed in the 
present study. The primary reason for this was to be able to directly compare the effects 
of keto and non-keto amphetamines, and since the majority of the literature employs the 
aforementioned high, non-progressive doses, using similar doses provides the best way of 
directly comparing the two types of drugs. Conclusions about the relative toxicity of 
cathinones and amphetamines are therefore defendable. However, whether, or to what 
extent, the toxicity that is seen in animals also occurs in humans at common recreational 
doses in the first place is still unclear. 
 
6.6.3 In vitro studies 
 
The results from the in vitro study presented in this thesis (IV) demonstrated cytotoxic 
effects of 4-MMC and MDMC at millimolar concentrations. It is important to note that 
these results should not be translated in a way to suggest that these drugs are more 
neurotoxic in vivo, primarily because the actual in vivo data does not support this 
conclusion. Furthermore, these millimolar concentrations are around a thousand times 
higher than the low micromolar concentrations observed in human users (Logan et al., 
1998). At the more physiologically relevant concentrations, a decrease in toxicity was in 
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fact observed. Nonetheless, a number of factors known to mediate neurotoxicity in vivo, 
such as ROS generation and mitochondrial damage, are replicated in the SH-SY5Y cell line 
at these high concentrations (Wu et al., 2007; Wang et al., 2008), suggesting that the SH-
SY5Y cell line is a valid model for comparing and contrasting the effects of keto and non-
keto amphetamines and for investigating mechanisms potentially involved in producing 
toxic effects of these substances in vivo.  
 
6.7 Future directions 
 
The phenomenon of new and obscure psychoactive drugs occurring on the drug market 
via online distribution, which started in the early 2000’s but gained pace rapidly around 
2009, does not show any sign of slowing down. In fact, the number of new psychoactive 
substances which have been officially reported has been increasing every year since 2008, 
with over 80 new substances reported in 2013 alone (Fig. 2.2). The actual number of new 
substances may be even higher, considering the likelihood that not all new substances are 
rapidly detected by authorities. 
 
6.7.1 Ongoing screening of new drugs 
 
As new drugs continue to appear, it is important to continuously keep an eye on this new 
online drug market, and to identify new trends and substances in order to subject them 
to scientific scrutiny. With the number of new substances being reported every year, it is 
currently impossible to study each compound in-depth. Nonetheless, preclinical and in 
vitro studies of the most popular compounds is clearly warranted in order to make a 
reasonable risk assessment, to identify mechanisms involved in producing potential 
neurotoxic effects, and to identify possible strategies for harm reduction.  
6.7.2 Answers in human studies 
 
In light of the occurrence of new amphetamines and other psychedelic drugs, it is 
important to note the recently renewed interest in these substances as potential 
treatments for a wide range of mental disorders, including depression, anxiety disorders 
and addiction. MDMA has received the most interest so far in terms of completed studies 
(Mithoefer et al., 2011; Chabrol, 2013; Mithoefer et al., 2013; Oehen et al., 2013) and 
ongoing clinical trials (NCT01211405, NCT01793610 and NCT01689740) for treatment of 
post-traumatic stress disorder. The antidepressant effect of ketamine has been known for 
some time, but is now again receiving more attention (Berman et al., 2000; Salvadore and 
Singh, 2013; Moaddel et al., 2014 and NCT01558063). Also 5-HT hallucinogens such as 
lysergic acid diethylamide and psilocybin are being tested for applications ranging from 
anxiolysis to smoking cessation (Grob et al., 2011; Gasser et al., 2014 and NCT01943994).  
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Interestingly, the results from the published studies have so far been quite favorable. The 
studies are also important for another reason, as they can provide clear answers 
regarding the effects of drugs such as MDMA at relevant clinical and recreational doses in 
humans. After around three decades of research on MDMA there are still a number of 
unanswered questions about its long-term effects on humans. It is therefore advisable 
that the ongoing and future clinical studies of these substances include carefully planned 
and meticulously designed cognitive tests and, when possible, neuroimaging 
experiments, in order to provide more definitive answers regarding the effects of these 
drugs in humans. 
 
6.7.3 A toolbox of novel psychoactive substances 
 
The rise of the novel psychoactive substance phenomenon is often considered mostly in 
terms of its potential public health threat. Although this is not unwarranted - it is always 
best to approach unknown compounds with caution – it is perhaps not right to only see it 
in this light. The results presented in this thesis emphasize that novel does not necessarily 
imply more dangerous. In fact, new substances may even have more favorable safety 
profiles, compared to their more well-known analogues and counterparts. Aside from 
empathogenic phenethylamines such as 4-MMC and MDMC discussed in this thesis, other 
novel psychoactive substances include tryptamines, cannabinoids and ketamine 
analogues. These are exactly the classes of drugs which have been showing very favorable 
results in recent clinical trials. Therefore, novel psychoactive substances represent not 
only a threat to public health but also, when approached systematically and studied 
meticulously, a toolbox filled with an almost unlimited amount of new tools, with 
potential applications in psychiatry, neurology and possibly other branches of medicine. 
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7. Conclusions 
 
 
Based on the results of specific studies described in this thesis, it can be concluded that: 
1. In rats, treatment with MDMA during adolescence is less toxic to 5-HT neurons in the 
PFC compared to treatment in early adulthood. However, no such age-related effect on 5-
HT neurotoxicity was observed in humans. 
 
2. The substituted cathinone 4-MMC produces no evidence of neurotoxicity in mice or 
rats. MDMC produces 5-HT toxicity similar to MDMA in rats, although the effect may be 
less severe. Furthermore, neither drug produces any consistent long-term effects on 
cognition or other neurobehavioral measurements in mice. 
 
3. The long-term effects of 4-MMC on rat brain activity are much less pronounced than 
those of METH. 
 
4. Specific differences in chemical properties between β-keto amphetamines and non-
keto amphetamines, such as altered redox reactivity, could play a role in their differing 
long-term effects.  
 
When translating these results, the following more general conclusions about the long-
term neuropharmacological and neurotoxic effects of cathinones can be drawn: 
 
1. Occasional recreational use of the substituted cathinones 4-MMC and MDMC does not 
appear to be more harmful than the use of amphetamines such as METH and MDMA. In 
fact, they may be less harmful.  
 
2. At present, there is no indication that these cathinones constitute an imminent and 
severe public health threat, as was initially feared. However, further work is needed 
before definitive conclusions about its safety in humans can be drawn. 
 
3. From a harm reduction perspective, the cathinones may be interesting because they 
produce similar subjective effects as amphetamines, but may have a more favourable 
safety profile. 
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